CN109106877A - 一种防治哺乳期妇女热邪壅盛型乳腺炎的中药组合物、其制备方法及药物制剂 - Google Patents
一种防治哺乳期妇女热邪壅盛型乳腺炎的中药组合物、其制备方法及药物制剂 Download PDFInfo
- Publication number
- CN109106877A CN109106877A CN201811282197.7A CN201811282197A CN109106877A CN 109106877 A CN109106877 A CN 109106877A CN 201811282197 A CN201811282197 A CN 201811282197A CN 109106877 A CN109106877 A CN 109106877A
- Authority
- CN
- China
- Prior art keywords
- ethyl alcohol
- water
- polyvinyl alcohol
- grams
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 115
- 210000000481 breast Anatomy 0.000 title claims abstract description 58
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 240000005373 Panax quinquefolius Species 0.000 title claims abstract description 20
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 20
- 230000002265 prevention Effects 0.000 title claims abstract description 14
- 239000000825 pharmaceutical preparation Substances 0.000 title description 3
- 244000179560 Prunella vulgaris Species 0.000 claims abstract description 39
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 39
- 235000010674 Prunella vulgaris Nutrition 0.000 claims abstract description 38
- 240000004307 Citrus medica Species 0.000 claims abstract description 35
- 229940079593 drug Drugs 0.000 claims abstract description 30
- 241000219357 Cactaceae Species 0.000 claims abstract description 29
- 241001302463 Viola mandshurica Species 0.000 claims abstract description 21
- 241000234479 Narcissus Species 0.000 claims abstract description 20
- 241001074093 Echinopsis Species 0.000 claims abstract description 19
- 240000002307 Solanum ptychanthum Species 0.000 claims abstract description 19
- 235000018081 Hibiscus syriacus Nutrition 0.000 claims abstract description 18
- 244000130592 Hibiscus syriacus Species 0.000 claims abstract description 18
- 235000002594 Solanum nigrum Nutrition 0.000 claims abstract description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 148
- 235000019441 ethanol Nutrition 0.000 claims description 83
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 83
- 239000000843 powder Substances 0.000 claims description 67
- 239000000284 extract Substances 0.000 claims description 50
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 44
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 44
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 44
- 239000003292 glue Substances 0.000 claims description 36
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 32
- 239000007788 liquid Substances 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 25
- 239000000341 volatile oil Substances 0.000 claims description 25
- 244000025254 Cannabis sativa Species 0.000 claims description 24
- 238000001914 filtration Methods 0.000 claims description 23
- 238000000605 extraction Methods 0.000 claims description 21
- 108010010803 Gelatin Proteins 0.000 claims description 20
- 239000012153 distilled water Substances 0.000 claims description 20
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 20
- 229920000159 gelatin Polymers 0.000 claims description 20
- 239000008273 gelatin Substances 0.000 claims description 20
- 235000019322 gelatine Nutrition 0.000 claims description 20
- 235000011852 gelatine desserts Nutrition 0.000 claims description 20
- 235000009967 Erodium cicutarium Nutrition 0.000 claims description 19
- 240000003759 Erodium cicutarium Species 0.000 claims description 19
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 19
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 18
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 18
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 18
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims description 17
- 235000017491 Bambusa tulda Nutrition 0.000 claims description 17
- 241000244987 Daiswa polyphylla Species 0.000 claims description 17
- 235000018958 Gardenia augusta Nutrition 0.000 claims description 17
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims description 17
- 239000011425 bamboo Substances 0.000 claims description 17
- 239000000706 filtrate Substances 0.000 claims description 17
- 240000004670 Glycyrrhiza echinata Species 0.000 claims description 15
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 15
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 15
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 15
- 241000612118 Samolus valerandi Species 0.000 claims description 15
- 229940010454 licorice Drugs 0.000 claims description 15
- 240000005702 Galium aparine Species 0.000 claims description 14
- 235000014820 Galium aparine Nutrition 0.000 claims description 14
- 238000009835 boiling Methods 0.000 claims description 13
- 239000002398 materia medica Substances 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 11
- 239000012188 paraffin wax Substances 0.000 claims description 9
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 9
- 229920000053 polysorbate 80 Polymers 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- -1 tincture Substances 0.000 claims description 9
- 239000011521 glass Substances 0.000 claims description 8
- 241000931143 Gleditsia sinensis Species 0.000 claims description 7
- 230000005484 gravity Effects 0.000 claims description 7
- 239000002674 ointment Substances 0.000 claims description 7
- 238000001556 precipitation Methods 0.000 claims description 7
- 238000007873 sieving Methods 0.000 claims description 7
- 229940098465 tincture Drugs 0.000 claims description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 claims description 6
- 238000001704 evaporation Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 230000001376 precipitating effect Effects 0.000 claims description 6
- 238000012958 reprocessing Methods 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 239000007765 cera alba Substances 0.000 claims description 4
- 150000002085 enols Chemical class 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 244000111489 Gardenia augusta Species 0.000 claims description 3
- 239000004698 Polyethylene Substances 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 238000007598 dipping method Methods 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 229920003023 plastic Polymers 0.000 claims description 3
- 239000004033 plastic Substances 0.000 claims description 3
- 229920000573 polyethylene Polymers 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 229940099259 vaseline Drugs 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 2
- 244000082204 Phyllostachys viridis Species 0.000 claims 2
- 229920006335 epoxy glue Polymers 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 238000010025 steaming Methods 0.000 claims 1
- 235000019966 white bee wax Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 53
- 208000002193 Pain Diseases 0.000 abstract description 36
- 230000036407 pain Effects 0.000 abstract description 36
- 238000009472 formulation Methods 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 40
- 239000008280 blood Substances 0.000 description 40
- 239000007789 gas Substances 0.000 description 25
- 208000004396 mastitis Diseases 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 201000010099 disease Diseases 0.000 description 20
- 235000013336 milk Nutrition 0.000 description 20
- 239000008267 milk Substances 0.000 description 20
- 210000004080 milk Anatomy 0.000 description 20
- 239000000243 solution Substances 0.000 description 18
- 206010062717 Increased upper airway secretion Diseases 0.000 description 16
- 208000026435 phlegm Diseases 0.000 description 16
- 241001330002 Bambuseae Species 0.000 description 15
- 206010007247 Carbuncle Diseases 0.000 description 15
- 238000003745 diagnosis Methods 0.000 description 15
- 241000894006 Bacteria Species 0.000 description 14
- 240000001972 Gardenia jasminoides Species 0.000 description 14
- 206010042674 Swelling Diseases 0.000 description 14
- 210000004185 liver Anatomy 0.000 description 14
- 230000008961 swelling Effects 0.000 description 14
- 239000000796 flavoring agent Substances 0.000 description 13
- 235000019634 flavors Nutrition 0.000 description 13
- 230000006651 lactation Effects 0.000 description 13
- 230000001737 promoting effect Effects 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 12
- 210000002784 stomach Anatomy 0.000 description 12
- 210000005075 mammary gland Anatomy 0.000 description 11
- 206010000269 abscess Diseases 0.000 description 10
- 208000001848 dysentery Diseases 0.000 description 10
- 210000002216 heart Anatomy 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 10
- 231100000614 poison Toxicity 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 229930013930 alkaloid Natural products 0.000 description 9
- 230000004087 circulation Effects 0.000 description 9
- 235000009508 confectionery Nutrition 0.000 description 9
- 239000006071 cream Substances 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 8
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 8
- 208000025865 Ulcer Diseases 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 210000002445 nipple Anatomy 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 210000001015 abdomen Anatomy 0.000 description 7
- 150000003797 alkaloid derivatives Chemical class 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 230000036461 convulsion Effects 0.000 description 7
- 230000000474 nursing effect Effects 0.000 description 7
- 235000021251 pulses Nutrition 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 206010010904 Convulsion Diseases 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- 206010060710 Galactostasis Diseases 0.000 description 6
- 208000004880 Polyuria Diseases 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 210000004883 areola Anatomy 0.000 description 6
- 230000036760 body temperature Effects 0.000 description 6
- 230000035619 diuresis Effects 0.000 description 6
- 235000013350 formula milk Nutrition 0.000 description 6
- 210000000232 gallbladder Anatomy 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 230000035922 thirst Effects 0.000 description 6
- 231100000397 ulcer Toxicity 0.000 description 6
- 206010016717 Fistula Diseases 0.000 description 5
- 206010061926 Purulence Diseases 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 5
- 241001426376 Rhaponticum uniflorum Species 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000003890 fistula Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 229930182470 glycoside Natural products 0.000 description 5
- 241000411851 herbal medicine Species 0.000 description 5
- 239000003440 toxic substance Substances 0.000 description 5
- 206010046901 vaginal discharge Diseases 0.000 description 5
- 206010008190 Cerebrovascular accident Diseases 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 206010023126 Jaundice Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 4
- 241000447727 Scabies Species 0.000 description 4
- 206010040047 Sepsis Diseases 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 210000000038 chest Anatomy 0.000 description 4
- 206010015037 epilepsy Diseases 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- 150000002338 glycosides Chemical class 0.000 description 4
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 4
- 229960004949 glycyrrhizic acid Drugs 0.000 description 4
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 4
- 235000019410 glycyrrhizin Nutrition 0.000 description 4
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 230000003447 ipsilateral effect Effects 0.000 description 4
- 201000005630 leukorrhea Diseases 0.000 description 4
- OPMNROCQHKJDAQ-FKSUSPILSA-N loline Chemical compound C1C[C@@H]2O[C@H]3[C@H](NC)[C@@H]2N1C3 OPMNROCQHKJDAQ-FKSUSPILSA-N 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 201000007227 lymph node tuberculosis Diseases 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000003340 mental effect Effects 0.000 description 4
- 230000019989 milk ejection Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000002574 poison Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 206010063409 Acarodermatitis Diseases 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 3
- 108010074051 C-Reactive Protein Proteins 0.000 description 3
- 241000675108 Citrus tangerina Species 0.000 description 3
- 201000000297 Erysipelas Diseases 0.000 description 3
- 206010017553 Furuncle Diseases 0.000 description 3
- 239000004378 Glycyrrhizin Substances 0.000 description 3
- 206010018498 Goitre Diseases 0.000 description 3
- 208000008454 Hyperhidrosis Diseases 0.000 description 3
- 208000024818 Nipple disease Diseases 0.000 description 3
- 208000005374 Poisoning Diseases 0.000 description 3
- 208000004680 Rectal Fistula Diseases 0.000 description 3
- 208000004078 Snake Bites Diseases 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 206010002156 anal fistula Diseases 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000035606 childbirth Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 201000003872 goiter Diseases 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 208000014617 hemorrhoid Diseases 0.000 description 3
- 208000021760 high fever Diseases 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 239000010985 leather Substances 0.000 description 3
- 201000004792 malaria Diseases 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 210000004493 neutrocyte Anatomy 0.000 description 3
- 230000001151 other effect Effects 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 231100000572 poisoning Toxicity 0.000 description 3
- 230000000607 poisoning effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 208000005687 scabies Diseases 0.000 description 3
- 239000002689 soil Substances 0.000 description 3
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000001256 tonic effect Effects 0.000 description 3
- 150000003648 triterpenes Chemical class 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 2
- KSDSYIXRWHRPMN-UHFFFAOYSA-N 4'-O-beta-D-Galactopyranoside-6''-p-Coumaroylprunin-4',5,7-Trihydroxyflavanone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC(O)=C3C(=O)C2)C=C1 KSDSYIXRWHRPMN-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010063659 Aversion Diseases 0.000 description 2
- 208000031729 Bacteremia Diseases 0.000 description 2
- HJXMNVQARNZTEE-UHFFFAOYSA-N Butylphthalide Chemical compound C1=CC=C2C(CCCC)OC(=O)C2=C1 HJXMNVQARNZTEE-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 244000183685 Citrus aurantium Species 0.000 description 2
- 240000002319 Citrus sinensis Species 0.000 description 2
- 235000005976 Citrus sinensis Nutrition 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 206010010144 Completed suicide Diseases 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- 206010012374 Depressed mood Diseases 0.000 description 2
- 206010013954 Dysphoria Diseases 0.000 description 2
- 239000010282 Emodin Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000034507 Haematemesis Diseases 0.000 description 2
- 208000000616 Hemoptysis Diseases 0.000 description 2
- 241000218228 Humulus Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- DEMKZLAVQYISIA-ONJCETCRSA-N Liquiritin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc([C@@H]2Oc3c(C(=O)C2)ccc(O)c3)cc1 DEMKZLAVQYISIA-ONJCETCRSA-N 0.000 description 2
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000123069 Ocyurus chrysurus Species 0.000 description 2
- 240000002014 Phyllostachys nigra var. henonis Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- CKAHWDNDUGDSLE-ARLBYUKCSA-N Pseudolycorine Chemical compound C1N([C@@H]23)CCC3=C[C@H](O)[C@@H](O)[C@H]2C2=C1C=C(OC)C(O)=C2 CKAHWDNDUGDSLE-ARLBYUKCSA-N 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- ZPIKVDODKLJKIN-NSHDSACASA-N Senkyunolide Chemical compound C1CC=CC2=C1[C@H](CCCC)OC2=O ZPIKVDODKLJKIN-NSHDSACASA-N 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 208000004381 Uterine cervical erosion Diseases 0.000 description 2
- 235000009499 Vanilla fragrans Nutrition 0.000 description 2
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000000767 anti-ulcer Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 238000009412 basement excavation Methods 0.000 description 2
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 208000030270 breast disease Diseases 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 201000008252 cervix erosion Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 231100000895 deafness Toxicity 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 239000003337 fertilizer Substances 0.000 description 2
- OPMNROCQHKJDAQ-UHFFFAOYSA-N festucine Natural products C1CC2OC3C(NC)C2N1C3 OPMNROCQHKJDAQ-UHFFFAOYSA-N 0.000 description 2
- 208000003512 furunculosis Diseases 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 208000016354 hearing loss disease Diseases 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000010977 jade Substances 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- DEMKZLAVQYISIA-ZRWXNEIDSA-N liquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([C@H]2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-ZRWXNEIDSA-N 0.000 description 2
- 210000001365 lymphatic vessel Anatomy 0.000 description 2
- VVOAZFWZEDHOOU-UHFFFAOYSA-N magnolol Chemical compound OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000001114 myogenic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 150000003138 primary alcohols Chemical class 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 208000009146 rhinoscleroma Diseases 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- PHVSWPDOXIQPTN-UHFFFAOYSA-N sedanonic acid Chemical compound CCCCC(=O)C1CCCC=C1C(O)=O PHVSWPDOXIQPTN-UHFFFAOYSA-N 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 235000014101 wine Nutrition 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- LLWFHCJFZGXUAT-UMXPSMRGSA-N (1S,2R,18R,19R,22S,25R,28R,40S)-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5S,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-19-[[(2R)-2-amino-4-methylpentanoyl]amino]-22-(2-amino-2-oxoethyl)-5,15-dichloro-2,18,32,35,37-pentahydroxy-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carboxylic acid hydrochloride Chemical compound Cl.CC(C)C[C@@H](N)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2 LLWFHCJFZGXUAT-UMXPSMRGSA-N 0.000 description 1
- NEEWCTFFDQIISO-UHFFFAOYSA-N (1alpha,2alpha,3beta)-1,2,3-Trihydroxy-12-ursen-28-oic acid Natural products OC1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)C(C)C5C4=CCC3C21C NEEWCTFFDQIISO-UHFFFAOYSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- KZJWDPNRJALLNS-ICLVQLPZSA-N (3s,8s,9s,10r,13r,17r)-17-[(2r,5r)-5-ethyl-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1C1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-ICLVQLPZSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- AUNAUZZQBAIQFJ-UHFFFAOYSA-N 2,4,5-Trimethoxy-1-allylbenzene Chemical compound COC1=CC(OC)=C(OC)C=C1CC=C AUNAUZZQBAIQFJ-UHFFFAOYSA-N 0.000 description 1
- QNMKGMUGYVWVFQ-UHFFFAOYSA-N 2alpha-Hydroxyursolic acid Natural products CC12CC(O)C(O)C(C)(C)C1CCC1(C)C2CC=C2C3C(C)C(C)(C)CCC3(C(O)=O)CCC21C QNMKGMUGYVWVFQ-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- NGSWKAQJJWESNS-ZZXKWVIFSA-M 4-Hydroxycinnamate Natural products OC1=CC=C(\C=C\C([O-])=O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-M 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- HGUVPEBGCAVWID-KETMJRJWSA-N 7-O-(beta-D-glucosyl)isovitexin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1O)[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 HGUVPEBGCAVWID-KETMJRJWSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000209495 Acorus Species 0.000 description 1
- 244000205574 Acorus calamus Species 0.000 description 1
- 244000001632 Acorus gramineus Species 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000010470 Ageusia Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010002953 Aphonia Diseases 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010006298 Breast pain Diseases 0.000 description 1
- 206010006312 Breast swelling Diseases 0.000 description 1
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 1
- 235000011996 Calamus deerratus Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 241000183712 Cerinthe major Species 0.000 description 1
- 241000905957 Channa melasoma Species 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 235000000228 Citrus myrtifolia Nutrition 0.000 description 1
- 235000016646 Citrus taiwanica Nutrition 0.000 description 1
- 241000218158 Clematis Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010057254 Connective tissue inflammation Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 241000218176 Corydalis Species 0.000 description 1
- 244000168525 Croton tiglium Species 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010014020 Ear pain Diseases 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 241000380130 Ehrharta erecta Species 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 208000009331 Experimental Sarcoma Diseases 0.000 description 1
- 241000510678 Falcaria vulgaris Species 0.000 description 1
- 206010067143 Fistula discharge Diseases 0.000 description 1
- 206010016825 Flushing Diseases 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 241000175212 Herpesvirales Species 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 235000001018 Hibiscus sabdariffa Nutrition 0.000 description 1
- 240000004153 Hibiscus sabdariffa Species 0.000 description 1
- 241000825107 Hierochloe Species 0.000 description 1
- 235000015466 Hierochloe odorata Nutrition 0.000 description 1
- 241001504070 Huperzia Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021036 Hyponatraemia Diseases 0.000 description 1
- 206010021067 Hypopituitarism Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 241001183967 Isodon Species 0.000 description 1
- YNWXJFQOCHMPCK-UHFFFAOYSA-N Isoliquiritin Natural products OC1C(O)C(O)C(CO)OC1OC(C=C1)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O YNWXJFQOCHMPCK-UHFFFAOYSA-N 0.000 description 1
- UGNZSMZSJYOGNX-UHFFFAOYSA-N Isoviocristine Natural products O=C1C=C(C)C(=O)C2=CC3=CC(OC)=CC(O)=C3C(O)=C21 UGNZSMZSJYOGNX-UHFFFAOYSA-N 0.000 description 1
- 241001412304 Ixeris Species 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000635276 Lagotis glauca Species 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 241000244365 Ligusticum sinense Species 0.000 description 1
- FURUXTVZLHCCNA-UHFFFAOYSA-N Liquiritigenin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 235000011105 Magnolia hypoleuca Nutrition 0.000 description 1
- 240000004580 Magnolia hypoleuca Species 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 241000219071 Malvaceae Species 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 206010026889 Mastitis postpartum Diseases 0.000 description 1
- 208000006662 Mastodynia Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- 206010028140 Mucous stools Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- XQWFHGOIUZFQPJ-USTPAGJBSA-N Neoisoliquiritigenin Natural products O=C(/C=C/c1ccc(O)cc1)c1c(O)cc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O2)cc1 XQWFHGOIUZFQPJ-USTPAGJBSA-N 0.000 description 1
- XQWFHGOIUZFQPJ-LXGDFETPSA-N Neoisoliquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C=C1O)=CC=C1C(=O)\C=C\C1=CC=C(O)C=C1 XQWFHGOIUZFQPJ-LXGDFETPSA-N 0.000 description 1
- XQWFHGOIUZFQPJ-UHFFFAOYSA-N Neoisoliquiritin Natural products OC1C(O)C(O)C(CO)OC1OC(C=C1O)=CC=C1C(=O)C=CC1=CC=C(O)C=C1 XQWFHGOIUZFQPJ-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 201000002451 Overnutrition Diseases 0.000 description 1
- 241000381142 Pachydermia Species 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- SYYHBUHOUUETMI-UHFFFAOYSA-N Pennogenin Natural products O1C2CC3C4CC=C5CC(O)CCC5(C)C4CCC3(C)C2(O)C(C)C21CCC(C)CO2 SYYHBUHOUUETMI-UHFFFAOYSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 244000064622 Physalis edulis Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 244000202052 Poncirus trifoliata Species 0.000 description 1
- 235000000404 Poncirus trifoliata Nutrition 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 206010036297 Postpartum hypopituitarism Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010057071 Rectal tenesmus Diseases 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 241001107098 Rubiaceae Species 0.000 description 1
- 235000005291 Rumex acetosa Nutrition 0.000 description 1
- FFWOKTFYGVYKIR-UHFFFAOYSA-N SJ000287077 Natural products C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1O FFWOKTFYGVYKIR-UHFFFAOYSA-N 0.000 description 1
- 241000593989 Scardinius erythrophthalmus Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 201000009895 Sheehan syndrome Diseases 0.000 description 1
- 238000003457 Shi epoxidation reaction Methods 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- 235000001238 Solanum aculeastrum Nutrition 0.000 description 1
- 241000047359 Solanum aculeastrum Species 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 240000006688 Telosma cordata Species 0.000 description 1
- 235000017352 Telosma cordata Nutrition 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 240000006909 Tilia x europaea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 244000078912 Trichosanthes cucumerina Species 0.000 description 1
- 241000543657 Triglochin Species 0.000 description 1
- DWCSNWXARWMZTG-UHFFFAOYSA-N Trigonegenin A Natural products CC1C(C2(CCC3C4(C)CCC(O)C=C4CCC3C2C2)C)C2OC11CCC(C)CO1 DWCSNWXARWMZTG-UHFFFAOYSA-N 0.000 description 1
- 206010044684 Trismus Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010046814 Uterine prolapse Diseases 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 241000870995 Variola Species 0.000 description 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
- 244000304948 Viola papilionacea Species 0.000 description 1
- 235000002254 Viola papilionacea Nutrition 0.000 description 1
- 244000137773 Viola philippica Species 0.000 description 1
- 244000172533 Viola sororia Species 0.000 description 1
- 241001106476 Violaceae Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000009916 Yoshida Sarcoma Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 208000020560 abdominal swelling Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- RKFAZBXYICVSKP-AATRIKPKSA-N alpha-asarone Chemical compound COC1=CC(OC)=C(\C=C\C)C=C1OC RKFAZBXYICVSKP-AATRIKPKSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- RXVGBQCEAQZMLW-UHFFFAOYSA-N alpha-solanine Natural products CC1CCC2C(C)C3C(CC4C5CC=C6CC(CCC6(C)C5CCC34C)OC7OC(CO)C(O)C(OC8OC(CO)C(O)C(O)C8O)C7OC9OC(CO)C(O)C(O)C9O)N2C1 RXVGBQCEAQZMLW-UHFFFAOYSA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- WLXGUTUUWXVZNM-UHFFFAOYSA-N anthraglycoside A Natural products C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1OC1OC(CO)C(O)C(O)C1O WLXGUTUUWXVZNM-UHFFFAOYSA-N 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- RKFAZBXYICVSKP-UHFFFAOYSA-N beta- asarone Natural products COC1=CC(OC)=C(C=CC)C=C1OC RKFAZBXYICVSKP-UHFFFAOYSA-N 0.000 description 1
- 102000007478 beta-N-Acetylhexosaminidases Human genes 0.000 description 1
- 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 description 1
- RKFAZBXYICVSKP-WAYWQWQTSA-N beta-asarone Chemical group COC1=CC(OC)=C(\C=C/C)C=C1OC RKFAZBXYICVSKP-WAYWQWQTSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229950005197 butylphthalide Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- HFGSQOYIOKBQOW-ZSDYHTTISA-N corosolic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C HFGSQOYIOKBQOW-ZSDYHTTISA-N 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010064 diabetes insipidus Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- WQLVFSAGQJTQCK-VKROHFNGSA-N diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 description 1
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 208000007176 earache Diseases 0.000 description 1
- 208000002296 eclampsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 208000022532 enlargement of lymph nodes Diseases 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 125000005909 ethyl alcohol group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- XGVJWXAYKUHDOO-UHFFFAOYSA-N galanthidine Natural products C1CN2CC3=CC=4OCOC=4C=C3C3C2C1=CC(O)C3O XGVJWXAYKUHDOO-UHFFFAOYSA-N 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 150000002342 glycyrrhetinic acids Chemical class 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003760 hair shine Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000017525 heat dissipation Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 231100000437 hepatocellular injury Toxicity 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 description 1
- YNWXJFQOCHMPCK-LXGDFETPSA-N isoliquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C=C1)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O YNWXJFQOCHMPCK-LXGDFETPSA-N 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- FURUXTVZLHCCNA-AWEZNQCLSA-N liquiritigenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-AWEZNQCLSA-N 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- XGVJWXAYKUHDOO-DANNLKNASA-N lycorine Chemical compound C1CN2CC3=CC=4OCOC=4C=C3[C@H]3[C@H]2C1=C[C@H](O)[C@H]3O XGVJWXAYKUHDOO-DANNLKNASA-N 0.000 description 1
- KQAOMBGKIWRWNA-UHFFFAOYSA-N lycorine Natural products OC1C=C2CCN3C2C(C1O)c4cc5OCOc5cc34 KQAOMBGKIWRWNA-UHFFFAOYSA-N 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 238000009607 mammography Methods 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 210000001767 medulla oblongata Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000020823 overnutrition Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- SYYHBUHOUUETMI-WJOMMTHPSA-N pennogenin Chemical compound C([C@@]12[C@H]([C@@]3([C@@]4(C)CC[C@@H]5[C@@]6(C)CC[C@H](O)CC6=CC[C@H]5[C@@H]4C[C@@H]3O2)O)C)C[C@@H](C)CO1 SYYHBUHOUUETMI-WJOMMTHPSA-N 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229930015704 phenylpropanoid Natural products 0.000 description 1
- KZXBZVDIQWOGQH-UHFFFAOYSA-N physcion Chemical compound C1=C(C)C=C2C(=O)C3C=C(OC)C=C(O)C3C(=O)C2=C1O KZXBZVDIQWOGQH-UHFFFAOYSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000004382 potting Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- KLJOYDMUWKSYBP-SLEMLFNQSA-N pretazettine Natural products CO[C@H]1C[C@@H]2N(C)C[C@@H]3O[C@@H](O)c4cc5OCOc5cc4[C@]23C=C1 KLJOYDMUWKSYBP-SLEMLFNQSA-N 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 210000001034 respiratory center Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000008265 rhamnosides Chemical class 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- HGUVPEBGCAVWID-UHFFFAOYSA-N saponarin Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)C2C(C(O)C(O)C(CO)O2)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 HGUVPEBGCAVWID-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- YLWAQARRNQVEHD-UHFFFAOYSA-N sekisanoline Natural products CN1CC2(O)OCC3=CC=4OCOC=4C=C3C32C1CC(OC)C=C3 YLWAQARRNQVEHD-UHFFFAOYSA-N 0.000 description 1
- 229930183325 senkyunolide Natural products 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 235000003513 sheep sorrel Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- MOCOXAJEZKHXSF-IHMBCTQLSA-M sodium;(2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylate Chemical compound [Na+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MOCOXAJEZKHXSF-IHMBCTQLSA-M 0.000 description 1
- ZGVSETXHNHBTRK-OTYSSXIJSA-N solanine Chemical compound O([C@H]1[C@@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@@H]5N6C[C@@H](C)CC[C@@H]6[C@H]([C@@H]5[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZGVSETXHNHBTRK-OTYSSXIJSA-N 0.000 description 1
- 229940031352 solanine Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- YLWAQARRNQVEHD-PBZHRCKQSA-N tazettine Chemical compound O([C@]1(O)CN2C)CC3=CC=4OCOC=4C=C3[C@]31[C@@H]2C[C@H](OC)C=C3 YLWAQARRNQVEHD-PBZHRCKQSA-N 0.000 description 1
- 208000012271 tenesmus Diseases 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- NGSWKAQJJWESNS-ZZXKWVIFSA-N trans-4-coumaric acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-N 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 235000020097 white wine Nutrition 0.000 description 1
- 239000009137 wuling Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 235000021247 β-casein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/33—Cactaceae (Cactus family), e.g. pricklypear or Cereus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/43—Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/483—Gleditsia (locust)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/86—Violaceae (Violet family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种防治哺乳期妇女热邪壅盛型乳腺炎的中药组合物,其主要由仙人掌、紫花地丁、夏枯草、漏芦、枳实、龙葵、石菖蒲、木槿花、水仙根、厚朴等药物按照一定重量配比制备而成。本发明同时涉及该中药组合物的制备方法以及由其制备的外用剂型。本发明的全方具有清热解毒、活血行气、化瘀利水、散结止痛的功效,防治哺乳期妇女热邪壅盛型乳腺炎疗效确切。
Description
技术领域
本发明涉及中药领域,具体涉及一种防治哺乳期妇女热邪壅盛型乳腺炎的中药组合物及其制备方法。
背景技术
乳腺炎是乳腺的急性化脓性感染,是乳腺管内和周围结缔组织炎症,多发生于产后哺乳期的妇女,尤其是初产妇更为多见。有文献报道,初产妇中患有乳腺炎的人数占比为50%,乳腺炎患者中,初产妇与经产妇之比为24:1。乳腺炎在哺乳期的任何时间均可发生,但以产后3~4周最为常见,故又称产褥期乳腺炎。
乳腺炎初期症状多表现为乳汁不畅,乳房胀痛,皮温高,压痛;因乳汁的淤滞,静脉和淋巴的回流不畅,乳房局部出现边界不清的硬结。此阶段如能正确处理,则炎症可消散。
哺乳期妇女乳腺炎的病因主要包括以下几个方面:
1.细菌的入侵 本病致病菌多数为金黄葡萄球菌,少数为链球菌。细菌由乳头皮肤破裂处或乳晕皲裂处进入,沿淋巴管蔓延至乳腺小叶间及腺小叶的脂肪和纤维组织中,引起乳房急性化脓性蜂窝组织炎。亦有少数病例产后发生其他部位的感染并发症,细菌经血循环播散至乳房,引起发病。
乳汁淤积 乳汁有利于侵入细菌的繁殖。乳汁淤积的原因有:①乳头过小或内陷而产前又未能及时矫正,使婴儿吸乳困难,甚至不能哺乳。②乳汁过多,排空不完全。产妇不了解乳汁的分泌情况,多余乳汁不能及时排出而保留在乳内。③乳腺管阻塞使排乳困难,如乳管本身的炎症、肿瘤及外在压迫,均可影响正常哺乳。
乳头皲裂 分娩后产妇未能掌握正确的哺乳技巧,或婴儿的含吮不正常,或过度地在乳头上使用肥皂或乙醇干燥剂之类刺激物以及婴儿口腔运动功能的失调等造成乳头皲裂,使细菌沿乳头小裂口入侵,并且经淋巴管到达皮下及乳叶间组织而形成感染。乳头皲裂时,哺乳疼痛,不能使乳汁充分吸出,致乳汁淤积,为入侵细菌创造了繁殖条件。
检查方法
1.血常规 白细胞总数及中性粒细胞数增加。
细菌学检查
(1)血液细菌培养:一般应隔天1次,抽血做细菌培养,直到阴性为止。抽血时间最好选择在预计发生寒战、高热前,可提高阳性率。对临床表现极似菌血症而血液培养多次阴性者,应考虑厌氧菌感染的可能,可抽血做厌氧菌培养。
其他辅助检查:
X线钼靶摄片 乳房皮肤肿胀增厚,间质阴影增生扭曲,血管阴影明显增加,应用抗生素后炎症变化明显改变。
超检查 无损伤检查的首选。声像特点:①炎症肿块,边界不甚清楚,内部回声增厚增强,光点不均匀;②乳汁潴留,为无回声的小暗区;③脓肿形成,声像显示内部不均匀的液体暗区,边缘模糊,肿块局部有增厚,有时有分层现象,脓肿后方回声增强。
并发症
1.脓毒血症和菌血症 病程进入急性化脓性乳腺炎阶段,病人可并发脓毒血症和菌血症。此时病人持续高热,面色潮红,谵妄。可出现转移性脓肿。
乳房瘘管 脓肿形成期,脓肿可向内或向外破溃,形成皮肤破口和乳腺瘘管。如处理不当可形成长期不愈的脓瘘或乳瘘,临床可见从瘘管排出乳汁及脓液。
发病机制
乳汁淤积和细菌侵入是乳腺炎的两个重要因素。有文献报道,约40%正常产妇的乳汁中含有金黄葡萄球菌和白葡萄球菌,但不引起发病。初产妇易发急性乳腺炎与其乳汁中含有较多的脱落上皮细胞和组织碎屑引起乳管的阻塞有关。阻塞乳管可使乳房组织的活力降低,加之乳汁淤积的分解产物,使之更有利于细菌的生长繁殖,成为细菌很好的培养基。也有报道,哺乳后用吸乳器将乳汁吸尽,其患病率较哺乳后不吸尽乳汁的发病率可低1倍。
中医认识
乳腺炎属于中医学“乳痈”的范畴,俗称奶疮。多因乳头破碎,风邪外袭,或乳汁淤积,乳络阻滞,郁而化热所致,其来势急、易成脓;是以乳房部结块、肿胀疼痛、溃后脓出稠厚为主要表现的痈病类疾病;故临床上治疗的关键是抓住时机,辨证论治。中医学认为乳络不通是其主要病因,乳汁郁积日久化热,热盛肉腐成脓,发为乳痈,甚至反复传囊,形成乳瘘等变证;故强调及早治疗,在辨证论治的基础上,达到快速缓解症状、改善预后的目的;中医药对于乳腺炎的治疗方法多样,因地因人制宜,且不影响哺乳,保护母婴的健康;中医治疗乳腺炎,是建立在辨证论治的基础上缓解症状、改善预后,且无明显不良反应。
发明内容
发明人多年从事乳房疾病的防治工作,通过众多的临床医案筛选、分析、总结获知,热邪壅盛型在乳腺炎中占比最大,如果初起之时积极治疗,能够收到良好的治疗效果,且不易复发。因为哺乳期妇女大多数处于阳热状态,加之孕期、哺乳期营养过剩,运动量少,脾胃运化失常,水谷运化不及郁而化热,本身郁热的体质如果奶水过多,不能及时排空,则郁热积聚于乳房部位,热郁日久招致外邪入侵,形成痈毒。因而清热解毒是首要的治疗法则,同时辅助疏肝解郁、通乳消肿、活血利水等药物。通过众多热邪壅盛型乳腺炎患者诊疗用药的筛选,并且经过临床实验验证,确定了疗效肯定的中药组合物。
本发明的目的是提供一种疗效确切的用于防治哺乳期妇女热邪壅盛型乳腺炎的中药组合物,该中药组合物的制备方法以及包含该中药组合物的制剂。
本发明采用如下技术方案:
一种防治哺乳期妇女热邪壅盛型乳腺炎的中药组合物,其包括如下重量份的原料:
作为优选,其包括如下重量份的原料:
为了使各个组分更好地发挥药效,优选对原料药中的仙人掌、紫花地丁进行特殊提取,对夏枯草、厚朴、石菖蒲、青皮、枳实进行水蒸气蒸馏提取其挥发油。但是这些特殊工艺不能用于限制本发明的保护范围。
一种上述的防治哺乳期妇女热邪壅盛型乳腺炎的中药组合物的制备方法,其包括以下步骤:
(1)按照重量份秤取原料药物仙人掌、川芎、紫花地丁、夏枯草、漏芦、青皮、枳实、水仙根、玉柏石松、龙葵、木槿花、厚朴、石菖蒲、火焰草、水栀、皂角刺、天花粉、泽泻、重楼、四叶草、竹沥、生甘草备用。
(2)将所述重量配比的川芎、漏芦、水仙根、玉柏石松、龙葵、木槿花、火焰草、水栀、皂角刺、天花粉、泽泻、重楼、四叶草、生甘草加水煎煮2次;第一次加水量为没过药面2cm,沸腾之后文火煎煮50分钟;第二次加水量为没过药面1cm,沸腾之后文火煎煮30分钟;合并两次煎液,过滤获得滤液A。
(3)将所述重量配比的夏枯草、厚朴、石菖蒲、青皮、枳实用水蒸气提取方法收集挥发油备用。
(4)步骤(3)中收集了挥发油之后的夏枯草、厚朴、石菖蒲、青皮、枳实,继续利用步骤(2)得到水煎液A,所述水煎液A与滤液A合并,浓缩成比重为1.35的浸膏,再加90%-95%的乙醇进行醇沉,过滤沉淀后回收乙醇并浓缩,在45℃-50℃下干燥,制得干浸膏A。
(5)将所述重量配比的仙人掌、紫花地丁加90%-95%的乙醇进行回流提取,提取液回收乙醇,在45℃-50℃下干燥,得干浸膏B。
(6)合并干浸膏A和干浸膏B,将其粉碎成粉,再加入所述重量配比的竹沥干粉,混合均匀后再粉碎成细粉,喷入步骤(3)制得的夏枯草、厚朴、石菖蒲、青皮、枳实挥发油,再次搅拌均匀,即得。
制备方法之中,水煎方法、水蒸气提取方法以及乙醇回流提取方法均为本领域技术人员的常规方法。
一种包含上述的防治哺乳期妇女热邪壅盛型乳腺炎的中药组合物的中药制剂,其包括软膏剂、W/O型乳剂、酊剂、膜剂或外贴剂。
其中,所述软膏剂的制备方法为,将所述中药提取物细粉过100目筛之后,加入液体石蜡(1克过筛之后的药粉配比液体石蜡4ml)研磨至均匀细腻的糊状,进而采用等量递增法分次递加凡士林至全量即得。
其中,所述W/O型乳剂的制备方法为,取白蜂蜡、石蜡、液体石蜡,置于容器中,在水浴上加热熔化(1克中药组合物细粉配比白蜂蜡0.4克、石蜡0.4克、液体石蜡0.4ml),将中药组合物细粉溶解于70℃的水中,并且保持温度在70 ℃左右,充分溶解之后滤过不溶物,并且保持水相温度在70℃左右,将水相缓慢加入油相中,并且不断地向同一方向搅拌直至冷凝,即得。
其中,所述酊剂的制备方法为,取中药组合物细粉,置于广口瓶中,加入80%的乙醇(1克中药组合物细粉配比5ml乙醇),密闭浸渍3-5天,密闭的过程中时时加以振摇,3-5天之后滤过,残渣压榨,合并滤液与压榨液,静置24小时,滤过,即得。
其中,所述膜剂的制备方法为,取聚乙烯醇加入85%的乙醇(1克聚乙烯醇配比4ml乙醇)中浸泡过夜,滤过,沥干,重复处理一次,倾倒出乙醇,将聚乙烯醇60℃烘干,备用;取乙醇浸泡、烘干之后的聚乙烯醇置于三角瓶中,加入蒸馏水(1克乙醇浸泡之后烘干的聚乙烯醇配比10ml蒸馏水),在90℃的水浴上加热,使之溶化成胶液,滤过,备用;称取羧甲基纤维素钠和明胶置于三角瓶中(乙醇浸泡之后烘干的聚乙烯醇、羧甲基纤维素钠、明胶的质量比为5:2:2),加入蒸馏水(1克羧甲基纤维素钠配比20ml蒸馏水),在90℃水浴上加热并且不断搅拌,使其融化成胶液,滤过,备用;取上述制备成的聚乙烯醇胶液置于蒸发皿中,加入羧甲基纤维素钠和明胶的混合胶液(聚乙烯醇:羧甲基纤维素钠和明胶的混合胶液体积比为1:1),加入甘油(甘油与聚乙烯醇胶液的体积比为1:20)、聚山梨酯-80(聚山梨酯-80与聚乙烯醇胶液的体积比为1:4),混匀,静置脱气泡;取中药组合物细粉过100目筛之后加入上述溶液中(过筛之后的中药组合物细粉与乙醇浸泡之后烘干的固体聚乙烯醇的重量比为2:1),搅拌均匀,即得。
其中,所述外贴剂的制备方法为,取聚乙烯醇加入85%的乙醇中浸泡过夜(1克聚乙烯醇配比4ml乙醇),滤过,沥干,重复处理一次,倾倒出乙醇,将聚乙烯醇60℃烘干;取乙醇浸泡之后烘干的聚乙烯醇置于三角瓶中,加入蒸馏水(1克乙醇浸泡之后烘干的聚乙烯醇配比10ml蒸馏水),在90℃的水浴上加热,使之溶化成胶液,滤过,备用;称取羧甲基纤维素钠和明胶置于三角瓶中(乙醇浸泡之后烘干的聚乙烯醇、羧甲基纤维素钠、明胶的质量比为5:2:2),加入蒸馏水(1克羧甲基纤维素钠配比20ml蒸馏水),在90℃水浴上加热并且不断搅拌,使其融化成胶液,滤过,备用;取上述制备获得的聚乙烯醇胶液置于蒸发皿中,加入羧甲基纤维素钠和明胶的混合胶液(聚乙烯醇胶液:羧甲基纤维素钠和明胶的混合胶液=1:1,体积比),加入甘油(甘油:聚乙烯醇胶液=1:20,体积比),加入聚山梨酯-80(聚山梨酯-80与聚乙烯醇胶液的体积比为1:4),混匀,静置脱气泡;取中药组合物细粉过100目筛之后加入上述溶液中(过筛之后的中药组合物细粉与乙醇浸泡之后烘干的聚乙烯醇固体的质量比为2:1),搅拌均匀;取用玻璃板(玻璃板的尺寸依照实际需求确定),洗净,干燥,用75%的乙醇擦拭消毒,再涂擦少许石蜡,用吸管配合洗耳球吸取上述药液适量,滴注于玻璃板上,摊匀,水平面放置于半干,再置于60℃烘干,小心取下干药膜,用紫外线灭菌20分钟,装于无菌塑料袋中,即得。
本发明的有益效果在于:本发明中以仙人掌为君药,大剂量使用,发挥其行气活血、清热解毒的功效,同时辅助其他药物清热解毒、活血化瘀、行气利水、散结止痛。
本发明药物选择仙人掌、川芎、紫花地丁、夏枯草、漏芦、青皮、枳实、水仙根、玉柏石松、龙葵、木槿花、厚朴、石菖蒲、火焰草、水栀、皂角刺、天花粉、泽泻、重楼、四叶草、竹沥、生甘草22味中药组合发挥协同作用。
仙人掌为仙人掌科植物仙人掌,又名龙舌、观音刺;入药部位是其根及茎,亦可全株入药;性寒,味苦;主要成分含有三萜、苹果酸、琥珀酸、碳酸钾等,亦含有丰富的维生素B1、维生素B2、胡萝卜素,铁、锌等微量元素及氨基酸;如果经常食用,可以提神、健脑、强体。具有行气活血、清热解毒的功效。《陆川本草》载:仙人掌“消炎解毒,排脓生肌,主治疮痈疖肿”;《本草纲目》中记载:其味甘性平,补脾健胃,益脚力,除久泻。主要作用体现为:(1)延缓衰老,仙人掌除含有机体必须的全部氨基酸,还含有较高的Zn、Mn、Sr、Cr、Cu、Co等微量元素。它们是酶和维生素必须的活性因子,因其参与核酸代谢,从而影响机体的生长发育及寿命。其次仙人掌中含较高维生素E和多糖类物质,具有抗氧化能力,能够延缓衰老;(2)降血脂,仙人掌所含的维生素能抑制脂肪、胆固醇的吸收,起到降低血脂的作用;(3)消炎作用,民间常有利用仙人掌治疗炎症、疼痛、皮肤瘙痒等症,是仙人掌中的芳香族胺和糖类起作用,仙人掌提取物对金黄色葡萄球菌、大肠杆菌等有抑制作用;(4)抗溃疡,仙人掌提取物能增加胃黏膜血流量,对胃溃疡有明显的保护、治疗作用;(5)镇痛作用,仙人掌含有三萜皂苷发挥镇痛作用,可以明显减轻病人痛苦。本发明中选用仙人掌为君药,大剂量使用,发挥清热解毒、行气活血等作用。
川芎为伞形科植物川芎Ligusticum chuanxiong Hort.的干燥根茎。为多年生草本植物,根状茎呈不规则的结节状拳形,结节顶端有茎基团块,外皮黄褐色,有香气。夏季当茎上的节盘突出,并略带紫色时采挖,除去泥沙,晒后炕干,再去须根。气浓香,味苦、辛,微回甜,性温,稍有麻舌感;归肝、胆、心包经;具有活血行气、祛风燥湿、散结开郁之功效;临床多用于风冷头痛旋晕,月经不调,经闭痛经,胁痛腹疼,症瘕积聚,胸胁刺痛,跌扑肿痛,头痛,风湿痹痛等疾病的防治。《本经》记载其:“味辛,温” "主中风入脑头痛,寒痹,筋挛缓急,金创,妇人血闭无子"。《别录》认为其:"除脑中冷动,面上游风去来,目泪出,多涕唾,忽忽如醉,诸寒冷气,心腹坚痛,中恶,卒急肿痛,胁风痛,温中内寒"。《日华子本草》记载其:“治一切风,一切气,一切劳损,一切血,补五劳,壮筋骨,调众脉,破癥结宿血,养新血,治吐血及溺血,痔瘘,脑痈发背,瘰疬瘿赘,疮疥,排脓消瘀血”。川芎主要含有川芎嗪、黑麦草碱或含川哚,川芎萘呋内酯,丁基苯酞、新川芎内酯、洋川芎内酯、7-二羟基藁本内酯、洋川芎醌、香草酸、咖啡酸、原儿茶酸、阿魏酸、大黄酚、瑟丹酮酸、黑麦草碱、川芎酚等。药理作用表现为:(1)对中枢神经系统的作用,川芎有明显的镇静作用,川芎挥发油少量时对动物大脑的活动具有抑制作用,而对延脑呼吸中枢、血管运动中枢及脊髓反射中枢具有兴奋作用;(2)对冠脉循环的作用,川芎水提液及其生物碱能扩张冠状和血管,增加冠脉血流量,改善心肌缺氧状况;(3)对外周血管与血压的作用,川芎、川芎总生物碱和川芎嗪能使麻醉犬血管阻力下降,使脑、股动脉及下肢血流量增加。川芎生物碱、酚性部分和川芎嗪能抑制氯化钾与肾上腺素对家兔离体胸主动脉条的收缩作用;(4)对血小板聚集、血栓形成和血液粘滞度的影响,川芎嗪延长在体外ADP诱导的血小板凝聚时间,对已聚集的血小板有解聚作用;(5)对平滑肌的作用,川芎浸膏微量时能刺激受孕子宫,使其张力增高,收缩增强,终成挛缩;(6)抗菌作用,川芎对大肠、痢疾、变形、绿脓、伤寒、副伤寒杆菌及霍乱弧菌等有抑制作用,对某些致病性皮肤真菌也有抑制作用。本发明中以川芎为臣药,辅助君药仙人掌发挥活血行气功效,
紫花地丁(Viola philippica)为堇菜科植物紫花地丁的全草,别名地丁、金剪刀、紫地丁、箭头草、兔耳草、地丁草、野堇菜、光瓣堇菜等;紫花地丁味苦、微辛,性寒;归心、肝经;气微散泄;具有清热解毒、凉血消肿、清热利湿的作用;主治疔疮痄腮、痈肿、瘰疬、黄疸、痢疾、腹泻、瘰疬、丹毒、乳痈、肠痈、湿热与泻痢、目赤、喉痹、毒蛇咬伤等病证。本品具有抑菌、利胆、利尿和轻泻等作用;对金黄色葡萄球菌、卡他球菌、链球菌、肺炎双球菌均有抑制作用。含有苷类、黄酮类、黏液质、棕榈酸等。另含对羟基苯甲酸、反式对羟基桂皮酸、山柰酚-3-0-鼠李糖苷等成分。在本发明中紫花地丁作为臣药,辅助君药仙人掌发挥清热解毒之功效。
夏枯草为唇形科夏枯草属植物夏枯草 (Prunella vulgaris Linn.)的干燥果穗;该植物因“夏至后即枯”而得名,是常用传统中药之一;有降压、降糖、抗茵、抗炎、抗过敏及抗病毒等功效;临床多用于治疗目赤肿痛、畏光流泪、乳腺炎、高血压、淋巴结核、浸润性肺结核、单纯性甲状腺肿、腮腺炎、急性黄疸型传染性肝炎等。主要成分包括三萜、甾体类、黄酮类、香豆素类、苯丙素类、有机酸、挥发油、糖类等成分。对特异性免疫机能具有强抑制作用,因而可作为免疫抑制剂;由夏枯草和红糖组成的夏枯草胶囊可上调外周血T淋巴细胞亚群值;夏枯草提取物中的熊果酸、2α-羟基熊果酸、桦木酸及 2α、3α-二羟基乌苏 -2烯-28酸具有明显的抗过敏、抗炎活性;后者对经培养的RBL-2H3细胞中的β-氨基己糖苷酶的释放有显著的抑制作用,并呈现出量效关系。夏枯草水煎剂具有抗淋球菌作用,对耐药金葡菌敏感,作用优于盐酸去甲万古霉素;夏枯草中的水溶性阴离子多糖在100 mg/mL浓度时对单纯性疱疹病毒 l型、2型 (HSV-I,HSV-II)表现出明显的对抗活性。夏枯草味苦、辛,性寒,归肝、胆经,具有清肝火、散郁结的功效,多用于治疗痰火郁结所致的瘿瘤,又可消散痈肿,在本方中用量较大,软坚散结的同时防治乳痈。
枳实为芸香科植物酸橙(Citrus aurantium)及其栽培变种或甜橙(Citrussinensis Osbeck)的干燥幼果;其味苦、辛、酸,性温,归脾、胃经;具有破气消积、化痰散痞的作用,用于积滞内停、痞满胀痛、痰滞气阻胸痹、结胸、子宫脱垂等症。主要含有黄酮类、生物碱类、挥发油类成分。枳实提取物能有效清除羟自由基、超氧阴离子自由基、DP-PH自由基,从而发挥抑制脂质过氧化的作用;枳实挥发油对耐药金葡萄球菌有抑制作用,柠檬烯有祛痰、抗菌的作用;芳樟醇有防腐抗菌、抗病毒、镇静的作用;枳实挥发油能显著减少醋酸引起的小鼠扭体反应次数及小鼠自发活动次数,表现出一定程度的镇痛和中枢抑制作用;枳实提取物治疗组与糖尿病模型组比较,血糖水平显著降低,谷胱甘肽含量显著增加,谷胱甘肽过氧化物酶活性、丙二醛和NO含量显著降低, 超氧化物歧化酶活性增加;枳实提取物具有增强肝脏抗氧化能力、降低肝细胞损伤作用,高剂量时能显著降低血糖。本方中枳实发挥行气、软坚散结的作用。
本发明中所用漏芦为祁州漏芦,祁州漏芦(Rhaponticum unif lorum (L .)DC)属于菊科管状花亚科祁州漏芦属植物祁州漏芦的根;具有清热解毒、消痈下乳之功效;早在《神农本草经》中就有“漏芦下乳汁……久服轻身益气,耳目聪明,不老延年”的记载,且将其列为上品;陶弘景指出“此药久服甚益人”;本品具有杀“粘”、止刺痛、清热、解毒、解表等作用,是妇科及乳腺科的常用中药;含有植物蜕皮激素、黄酮类、萜类、噻吩类、酸类等化学成分;漏芦提取物具有一定的抗炎、镇痛、耐缺氧及抗疲劳作用,水提物对二甲苯所致小鼠耳壳肿胀有抑制作用,能减少冰醋酸所致小鼠的扭体次数,延长缺氧情况下的存活时间;乙醇提取物能降低小鼠腹腔毛细血管通透性,抑制巴豆油性耳肿胀,对角叉菜胶引起的大鼠足趾浮肿有促进消退的作用,并能显著抑制大鼠炎性肉芽肿的形成,漏芦提取物对二甲苯所致小鼠耳壳肿胀有抑制作用,能减少冰醋酸所致小鼠的扭体次数,延长缺氧情况下的存活时间,小鼠游泳 45 min 后肝糖原的水平明显增加、乳酸水平明显减少,与对照组比较均有显著性差异;祁州漏芦可以显著诱导小鼠乳腺上皮细胞β-酪蛋白的mRNA表达水平,通过影响乳腺的乳汁分泌蛋白来提高泌乳质量。漏芦具有通乳、清热解毒之功效,在本方中发挥通透行气,防治乳痈的作用。
青皮为芸香利植物福橘或朱橘等多种橘类的未成热的果皮或幼果。一般在春末夏初时采收,但亦有延长至秋季采摘,晒干即得。主产于福建、浙江、四川等地。青皮含挥发油,且多含黄酮甙等。性味苦辛,微温,入肝、胆经。具有疏肝破气,散结消痰之功效。主治胸胁胃脘疼痛,疝气,食积,乳肿,乳核,久疟癖块。《本草经疏》记载:"青皮,性最酷烈,削坚破滞是其所长,然误服之,立损人真气,为害不泼。凡欲施用,必与人参、术、芍药等补脾药同用,庶免遗患,必不可单行也。"《珍珠囊》中记载:"青皮主气滞,破积结,少阳经下药也。陈皮治高,青皮治低。"《纲目》云:"青橘皮,其色青气烈,味苦而辛,治之以醋,所谓肝欲散,急食辛以散之,以酸泄之,以苦降之也。陈皮浮而升,入脾肺气分,青皮沉而降,入肝胆气分,一体二用,物理自然也。小儿消积,多用青皮,最能发汗,有汗者不可用,说出杨仁斋《直指方》,人罕知之。"李杲认为:"青皮,有滞气则破滞气,无滞气则损真气。又破滞削坚积,皆治在下者效。引药至厥阴之分,下食入太阴之仓。"朱震亨则曰:"青皮乃肝、胆二经气分药,故人多怒,有滞气,胁下有郁积或小腹疝疼,用之以疏通二经,行其气也。若二经虚者,当先补而后用之。又疏肝气加青皮,炒黑则入血分也"。
水仙根为石蒜科植物水仙的鳞茎;春、秋采挖较佳,将根头挖起后,截去苗茎、须根,洗净泥沙,用开水潦后,晒干;味苦微辛,性寒;人心、肺二经;主治痈肿疮毒,虫咬,鱼骨哽;含伪石蒜碱、石蒜碱、多花水仙碱、漳州水仙碱等多种生物碱;水仙生物碱发挥一定的抗癌和抗病毒活性,水仙总生物碱20~30毫克/公斤腹腔注射对大鼠Jensen肉瘤;小鼠Crocker肉瘤及艾氏腹水癌均有明显疗效。
玉柏石松又称玉柏,为石松科植物玉柏的全草,又名玉遂、千年柏、万年松;生于海拔800-1200米的山地林下。分布于我国东北和长江中上游高山;味酸,性温;具有轻身,益气,止渴之功效;《别录》曰∶生石上,如松。高五、六寸,紫花,用茎叶;《本草拾遗》记载:“取根茎浸酒,去风血,除风瘙,宜老”;玉柏石松主要含有生物碱、萜类化合物、甾体类化合物及它们的葡萄糖甙、蒽醌类化合物、大黄素甲醚、大黄素及大黄素葡萄糖甙等化学成分。
龙葵为茄科植物龙葵的全草,夏、秋采收;别名苦菜、苦葵、老鸦眼睛草、天茄子、后红子、水茄、天泡草、老鸦酸浆草等;生于路旁或田野中,全国各地均有分布;性寒味苦,具有清热、解毒、活血、消肿之功效;主治疮痈肿毒、皮肤湿疹、小便不利、丹毒、跌打扭伤、慢性气管炎、急性肾炎、白带过多、前列腺炎、痢疾等疾病;化学成分含有龙葵碱、澳茄胺、龙葵定碱、皂甙、维生素C、树脂。
木槿花为锦葵科植物木槿的花蕾,大暑至处暑间,选晴天早晨,花半开时采摘,晒干;主要分布于江苏、湖北、四川、河南、河北、陕西等地;别名里梅花、朝开暮落花、篱障花、白玉花、藩篱花、猪油花等;味甘苦,性凉;入脾、肺、肝经;具有清热,利湿,凉血、消疮、利小便等功效;主治肠风泻血、痢疾、带下病;化学成分含皂草黄甙、肌醇、粘液质;《日华子本草》云其:"治肠风泻血,赤白痢,并焙入药;作汤代茶,治风";《本草汇言》曰其:"能除诸热,滑利能导积滞,善治赤白积痢,干涩不通,下坠欲解而不解,捣汁和生白酒温饮";《本经逢原》认为:"红者治肠风血痢,白者治白带白痢"。
厚朴是木兰科植物厚朴的干皮、根皮及枝皮,又名厚皮、重皮、赤朴、油朴、川朴、紫油厚朴。原产于湖北,现多栽培。气香,味辛辣,微苦,性温;归脾经、胃经、肺经、大肠经。属化湿药,具有燥湿消痰、下气除满的功效;主治湿滞伤中、脘痞吐泻、食积气滞、腹胀便秘、痰饮喘咳、虫积、心脾不调、肾气弱、腹满痛大便闭、小儿吐泻、胃虚泄泻及有痰惊等。厚朴具有肌肉松弛作用,小剂量兴奋肠管平滑肌,而大剂量具有抑制作用;具有抗溃疡的作用,有显著的中枢抑制作用;降血压,抗病原微生物,抗肿瘤;还有抗血小板和抑制细胞内钙流动等作用。含挥发油、生物碱、皂苷、厚朴酚、厚朴新酚以及鞣质和微量烟酸等。
石菖蒲为天南星科植物石菖蒲的根茎,别名昌本、菖蒲、昌阳、九节菖蒲、水剑草、香草等。生长于山涧泉流附近或泉流的水石间,分布于长江流域及其以南各地,主产四川、浙江、江苏等地。味辛,性微温;归心、肝、脾、肺、膀胱经;具有开窍,豁痰,理气,活血,散风,去湿之功效。主治癫痫,痰厥,热病神昏,健忘,气闭耳聋,心胸烦闷,胃痛,腹痛,风寒湿痹,痈疽肿毒,跌打损伤等疾病。根茎和叶中均含挥发油,其主要成分是β-细辛醚、细辛醚,其次为石竹烯、α-葎草烯、石菖醚等,还含氨基酸、有机酸和糖类。《本经》云其:"主风寒湿痹,咳逆上气,开心孔,补五脏,通九窍,明耳目,出音声";《别录》记载:"主耳聋,痈疮,温肠胃,止小便利,四肢湿痹,不得屈伸,小儿温疟,身积热不解,可作浴汤,聪耳目,益心智";《药性论》认为:"治风湿顽痹,耳鸣,头风,泪下,杀诸虫,治恶疮疥瘙";《日华子本草》则记载:"除风下气,除烦闷,止心腹痛,霍乱转筋。治客风疮疥,涩小便,杀腹藏虫。耳痛:作末、炒,承热裹窨,甚验"。
火焰草为茜草科火焰草属藤本植物,原产美洲巴拉圭、乌拉圭等地,近年来我国从国外引种栽培,是一种观赏价值极高的新型花卉。火焰草植株蔓生能力强,生长茂盛,花朵密生,花形筒状,花瓣红色,前端黄色,十分艳丽,可盆栽或利用花架做成各种造型观赏。性凉,味辛、甘,微苦,无毒。具有清热解毒、凉血止血的功效。主治热毒疮疡、乳痈、丹毒、无名肿毒、水火烫伤、咽喉肿痛、牙龈炎、血热吐血、咯血、鼻衄、外伤出血等。
水栀为茜草科植物大花栀子的果实。分布于我国中部及南部。味苦,性寒。能散热毒,治扭伤。
皂角刺为豆科植物皂荚的棘刺。全年可采,以9月至翌年3月间为宜。主产于江苏、湖北、河北、山西、河南、山东等地。味辛咸,性温。具有搜风,拔毒,消肿,排脓之功效。主治痈肿,疮毒,疠风,癣疮,胎衣不下。化学成分含黄酮甙、酚类,氨基酸。《本草衍义补遗》云其:"治痈疽已溃,能引至溃处。"《纲目》曰:"治痈肿,妒乳,风疠恶疮,胞衣不下,杀虫。"《本草崇原》认为:"去风化痰,败毒攻毒,定小儿惊风发搐,攻痘疮起发,化毒成浆"。
天花粉为葫芦科植物栝楼的根;春、秋均可采挖,以秋季采者为佳;全国大部分地区有产,主产河南、广西、山东、江苏、贵州、安徽等地。性凉,味甘、苦、酸,入肺、胃经;具有生津,止渴,降火,润燥,排脓,消肿之功效;主治热病口渴,消渴,黄疸,肺燥咳血,痈肿,痔瘘等病。《本经》云其:"主消渴,身热,烦满,大热,补虚安中,续绝伤"。《别录》曰:"除肠胃中痼热,唇干,口燥,短气。通月水,止小便利"。《日华子本草》认为该药:"通小肠,排脓,消肿毒,生肌长肉,消瘀血。治热狂时疾,乳痈,发背,痔瘘疮疖"。
泽泻为泽泻科植物泽泻的块茎,多年生沼泽植物;冬季叶子枯萎时,采挖块茎,除去茎叶及须根,洗净,用微火烘干,再撞去须根及粗皮入药;生于沼泽边缘,分布于黑龙江、吉林、辽宁、河北、河南、山东、江苏,浙江等地。味甘,性寒;归肾、膀胱经;具有利水、渗湿、泄热之功效;主治小便不利,水肿胀满,呕吐,泻痢,痰饮,脚气,淋病,尿血等证。主要含有三萜类化合物、挥发油、生物碱、天门冬素、植物甾醇、植物甾醇甙、脂肪酸、树脂、蛋白质和淀粉;主要药理作用体现为利尿、影响脂质代谢等。《本草衍义》曰:"泽泻,其功尤长于行水。张仲景曰,水蓄渴烦,小便不利,或吐或泻,五苓散主之。方用泽泻,故知其用长于行水。《本经》又引扁鹊云,多服病人眼涩,诚为行去其水。张仲景八味丸用之者,亦不过引接桂、附等归就肾经,别无他意。凡服泽泻散人,未有不小便多者;小便既多,肾气焉得复实,今人止泄精,多不敢用。"《纲目》则云:"泽泻,气平,味甘而淡,淡能渗泄,气味俱薄,所以利水而泄下。脾胃有湿热,则头重而目昏耳鸣,泽泻渗去其湿,则热亦随去,而土气得令,消气上行,天气明爽,故泽泻有养五脏、益气力、治头旋,聪明耳目之功,若久服则降令太过,清气不升,真阴潜耗,安得不目昏耶,仲景地黄丸,用茯苓、泽泻者,乃取其泻膀胱之邪气,非引接也,古人用补药,必兼泻邪,邪去则补药得力,一辟一阖,此乃玄妙,后世不知此理,专一于补,所以久服必至偏胜之害也"。
重楼为百合科植物云南重楼或七叶一枝花的干燥根茎。生于林下阴湿处,分布于四川、广西等地。秋后挖取,去除茎、叶、须根,晒干入药。性微寒,味苦;有小毒;归肝经。具有清热解毒、消肿止痛、凉肝定惊之功效;常用于疔疮痈肿、咽喉肿痛、蛇虫咬伤、跌扑伤痛、惊风抽搐等。含多种甾体皂甙,为薯蓣皂甙元和偏诺皂甙元的二、三、四糖甙,另含β-蜕皮激素、胡萝卜甙等。
四叶草为茜草科植物四叶葎或细四叶葎的全草,多年生草本植物,又名冷水丹、风车草、四方草;生于田畔、沟边等湿地,分布华北、长江流域以至福建等地;夏季花期采收,晒干或鲜用。味甘、性平;具有清热、利尿、解毒、消肿之功效;主治尿路感染、赤白带下、痢疾、痈肿、跌打损伤等疾病。《江西草药》称其:"清热解毒;消肿止痛,通利小便"。苏医《中草药手册》认为该药:"利尿消肿,抗癌。治尿路感染,赤白带下,子宫颈糜烂,化脓性炎症,并治脑脊髓膜炎,脓毒性败血症,痈疽,毒蛇咬伤,皮肤疮毒水肿,癌肿"。
竹沥为禾本科植物淡竹的茎用火烤灼而流出的液汁,别名竹汁、淡竹沥、竹油,全国大部分地区均产;性状为青黄色或黄棕色液汁,透明,具焦香气,以色泽透明者为佳。味甘、苦,性寒;归经入心、胃经;具有清热滑痰,镇惊利窍之功效;主治中风痰迷、肺热痰壅、惊风、癫痫、壮热烦渴、子烦、破伤风等病证。《别录》云其:"疗暴中风风痹,胸中大热,止烦闷"。《药性论》认为其能:"治卒中风失音不语。"《纲目》以本药:"治子冒风痉,解射罔毒。"《本草备要》认为该药:"消风降火,润燥行痰,养血益阴,利窍明日。治中风口噤,痰迷大热,风痉癫狂,烦闷消渴,血虚自汗"。
甘草为豆科植物甘草的根及根状茎;又名美草、蜜甘、蜜草、蕗草、国老、灵通、粉草等。生于向阳干燥的钙质草原、河岸砂质土等地;分布东北、西北、华北等地;秋季采挖,除去茎基、枝叉、须根等,截成适当长短的段,晒至半干,打成小捆,再晒至全干,切片入药。味甘,性平;入脾、胃、肺经;具有和中缓急、润肺、解毒、调和诸药之功效。生用,治咽喉肿痛,消化性溃疡,痈疽疮疡,解药毒及食物中毒;炙用,治脾胃虚弱,食少,腹痛便溏,劳倦发热,肺痿咳嗽,心悸,惊痫。甘草根及根茎含甘草甜素,为甘草酸的钾、钙盐;尚含甘草甙、甘草甙元、异甘草甙、异甘草元、新甘草甙、新异甘草甙等。甘草次酸对大白鼠移植的Oberling Guerin骨髓瘤有抑制作用,甘草酸单铵盐、甘草次酸钠及甘草次酸衍化物之混合物,对小白鼠艾氏腹水癌及肉瘤均有抑制作用,甘草甜素、甘草甙对大鼠腹水肝癌及小鼠艾氏腹水癌细胞能产生形态学上的变化,甘草甜素尚能抑制皮下移植的吉田肉瘤。《雷公炮炙沦》认为:"凡使甘草,须去头尾尖处,用酒浸蒸,从巳至午出,暴干,细锉使。一斤用酥七两,涂上炙,酥尽为度。又先炮令内外赤黄用良"。《本经》认为该药:"主五脏六腑寒热邪气,坚筋骨,长肌肉,倍力,金疮肿,解毒"。《别录》云其:"温中下气,烦满短气,伤脏咳嗽,止渴,通经脉,利血气,解百药毒"。《药性论》则认为甘草:"主腹中冷痛,治惊痫,除腹胀满;补益五脏;制诸药毒;养肾气内伤,令人阴(不)痿;主妇人血沥腰痛;虚而多热;加而用之"。现代医学临床研究证实,甘草可治愈多种疾病:①治疗胃、十二指肠溃疡,有较好的近期疗效。②治疗阿狄森氏病③治疗席汉氏综合征④治疗尿崩症⑤治疗肺结核⑥治疗支气管哮喘⑦治疗传染性肝炎⑧治疗急性血吸虫病⑨治疗疟疾⑩治疗血小板减少性紫癜⑾治疗腓肠肌痉挛⑿治疗先天性肌强直⒀治疗血栓性静脉炎⒁治疗子宫颈糜烂⒂治疗皮肤炎症⒃治疗手足皲裂⒄治疗眼科炎症⒅治疗冻伤。
本发明的药物组合物具有清热解毒、活血化瘀、行气利水、散结止痛等功效,用于哺乳期妇女热邪壅盛型乳腺炎的防治。
【具体实施方式】
为了加深对本发明的理解,下面结合实施例对本发明进行详细的描述,该实施例是示例性的,仅用于解释本发明,并不对保护范围构成限定。
【实施例1】本发明药物软膏剂
a)称取原料药物备用,原料药物剂量如下;
仙人掌 35克 | 川芎 30克 | 紫花地丁 30克 | 夏枯草 25克 |
漏芦 25克 | 青皮 25克 | 枳实 25克 | 水仙根 20克 |
玉柏石松 20克 | 龙葵 20克 | 木槿花 20克 | 厚朴 20克 |
石菖蒲 20克 | 火焰草 15克 | 水栀 15克 | 皂角刺 15克 |
天花粉 15克 | 泽泻 15克 | 重楼 12克 | 四叶草 10克 |
竹沥 10克 | 生甘草 6克 |
b)将所述重量配比的川芎、漏芦、水仙根、玉柏石松、龙葵、木槿花、火焰草、水栀、皂角刺、天花粉、泽泻、重楼、四叶草、生甘草14味中药加水煎煮2次;第一次加水量以没过药面2cm为宜,沸腾之后文火煎煮50分钟;第二次加水量以没过药面1cm为宜,沸腾之后文火煎煮30分钟;合并两次煎液,过滤获得滤液1;
c)将所述重量配比的夏枯草、厚朴、石菖蒲、青皮、枳实用水蒸气提取方法收集挥发油备用。夏枯草、厚朴、石菖蒲、青皮、枳实的水煎液(水煎液获取方法同步骤b)与滤液1合并,浓缩成比重为1.35的浸膏,加90%-95%的乙醇进行醇沉,过滤沉淀之后回收乙醇并浓缩,在45℃-50℃下干燥,制得干浸膏1;
d)将所述重量配比的仙人掌、紫花地丁加90%-95%的乙醇进行回流提取,提取液回收乙醇,在45℃-50℃下干燥,得干浸膏2;
e)合并干浸膏1和干浸膏2,将其粉碎成粉,再加入所述重量配比的竹沥干粉,混合均匀,再粉碎成细粉,喷入夏枯草、厚朴、石菖蒲、青皮、枳实挥发油,再次搅拌均匀,获得组方提取物约50克,50克组方提取物细粉过100目筛后,备用;
f)取步骤e)中获得的中药提取物细粉置于研钵之中,加入170ml液体石蜡,研磨至均匀细腻的糊状,进而采用等量递增法分次递加凡士林至全量,研匀即得。
【实施例2】本发明药物W/O型乳剂制备
a)称取原料药物备用,原料药物剂量如下:
仙人掌 40克 | 川芎 35克 | 紫花地丁 35克 | 夏枯草 28克 |
漏芦 28克 | 青皮 28克 | 枳实 28克 | 水仙根 22克 |
玉柏石松 22克 | 龙葵 22克 | 木槿花 22克 | 厚朴 22克 |
石菖蒲 22克 | 火焰草 18克 | 水栀 18克 | 皂角刺 18克 |
天花粉 18克 | 泽泻 18克 | 重楼 14克 | 四叶草 12克 |
竹沥 12克 | 生甘草 8克 |
b)将所述重量配比的川芎、漏芦、水仙根、玉柏石松、龙葵、木槿花、火焰草、水栀、皂角刺、天花粉、泽泻、重楼、四叶草、生甘草14味中药加水煎煮2次;第一次加水量以没过药面2cm为宜,沸腾之后文火煎煮50分钟;第二次加水量以没过药面1cm为宜,沸腾之后文火煎煮30分钟;合并两次煎液,过滤获得滤液1;
c)将所述重量配比的夏枯草、厚朴、石菖蒲、青皮、枳实用水蒸气提取方法收集挥发油备用。夏枯草、厚朴、石菖蒲、青皮、枳实的水煎液(水煎液获取方法同步骤b)与滤液1合并,浓缩成比重为1.35的浸膏,加90%-95%的乙醇进行醇沉,过滤沉淀后回收乙醇并浓缩,在45℃-50℃下干燥,制得干浸膏1;
d)将所述重量配比的仙人掌、紫花地丁加90%-95%的乙醇进行回流提取,提取液回收乙醇,在45℃-50℃下干燥,得干浸膏2;
e)合并干浸膏1和干浸膏2,将其粉碎成粉,再加入所述重量配比的竹沥干粉,混合均匀,再粉碎成细粉,喷入夏枯草、厚朴、石菖蒲、青皮、枳实挥发油,再次搅拌均匀,获得组方提取物约50克,50克组方提取物细粉过100目筛后,备用;
f)取白蜂蜡20克、石蜡20克、液体石蜡20ml,置于容器中,在水浴上加热熔化,并且保持温度在70 ℃左右,取步骤e)中获得的细粉,溶解于70℃的水中,充分溶解之后滤过不溶物,并且保持水相温度在70℃左右,将水相缓慢加入油相中,并且不断地向同一方向搅拌直至冷凝,即得。
【实施例3】本发明药物酊剂的制备
a)称取原料药物备用,原料药物剂量如下:
仙人掌 30克 | 川芎 25克 | 紫花地丁 25克 | 夏枯草 22克 |
漏芦 22克 | 青皮 22克 | 枳实 22克 | 水仙根 18克 |
玉柏石松 18克 | 龙葵 18克 | 木槿花 18克 | 厚朴 18克 |
石菖蒲 18克 | 火焰草 12克 | 水栀 12克 | 皂角刺 12克 |
天花粉 12克 | 泽泻 12克 | 重楼 10克 | 四叶草 8克 |
竹沥 8克 | 生甘草4克 |
b)将所述重量配比的川芎、漏芦、水仙根、玉柏石松、龙葵、木槿花、火焰草、水栀、皂角刺、天花粉、泽泻、重楼、四叶草、生甘草14味中药加水煎煮2次;第一次加水量以没过药面2cm为宜,沸腾之后文火煎煮50分钟;第二次加水量以没过药面1cm为宜,沸腾之后文火煎煮30分钟;合并两次煎液,过滤获得滤液1;
c)将所述重量配比的夏枯草、厚朴、石菖蒲、青皮、枳实用水蒸气提取方法收集挥发油备用。夏枯草、厚朴、石菖蒲、青皮、枳实的水煎液(水煎液获取方法同步骤b)与滤液1合并,浓缩成比重为1.35的浸膏,加90%-95%的乙醇进行醇沉,过滤沉淀后回收乙醇并浓缩,在45℃-50℃下干燥,制得干浸膏1;
d)将所述重量配比的仙人掌、紫花地丁加90%-95%的乙醇进行回流提取,提取液回收乙醇,在45℃-50℃下干燥,得干浸膏2;
e)合并干浸膏1和干浸膏2,将其粉碎成粉,再加入所述重量配比的竹沥干粉,混合均匀,再粉碎成细粉,喷入夏枯草、厚朴、石菖蒲、青皮、枳实挥发油,再次搅拌均匀,获得组方提取物约40克,40克组方提取物细粉过100目筛后,备用;
f) 取e)步骤中获得的细粉,置于广口瓶中,加入80%的乙醇200ml,密闭浸渍3-5天,密闭的过程中时时加以振摇,3-5天之后滤过,残渣压榨,合并滤液与压榨液,静置24小时,滤过,即得中药组合物酊剂;
【实施例4】本发明药物膜剂制备
a) 称取原料药物备用,原料药物配比如下:
仙人掌 38克 | 川芎 32克 | 紫花地丁 32克 | 夏枯草 26克 |
漏芦 26克 | 青皮 26克 | 枳实 26克 | 水仙根 20克 |
玉柏石松 20克 | 龙葵 20克 | 木槿花 20克 | 厚朴 20克 |
石菖蒲 20克 | 火焰草 16克 | 水栀 16克 | 皂角刺 16克 |
天花粉 16克 | 泽泻 16克 | 重楼 12克 | 四叶草 10克 |
竹沥 10克 | 生甘草 5克 |
b)将所述重量配比的川芎、漏芦、水仙根、玉柏石松、龙葵、木槿花、火焰草、水栀、皂角刺、天花粉、泽泻、重楼、四叶草、生甘草14味中药加水煎煮2次;第一次加水量以没过药面2cm为宜,沸腾之后文火煎煮50分钟;第二次加水量以没过药面1cm为宜,沸腾之后文火煎煮30分钟;合并两次煎液,过滤获得滤液1;
c)将所述重量配比的夏枯草、厚朴、石菖蒲、青皮、枳实用水蒸气提取方法收集挥发油备用。夏枯草、厚朴、石菖蒲、青皮、枳实的水煎液(水煎液获取方法同步骤b)与滤液1合并,浓缩成比重为1.35的浸膏,加90%-95%的乙醇进行醇沉,过滤沉淀后回收乙醇并浓缩,在45℃-50℃下干燥,制得干浸膏1;
d)将所述重量配比的仙人掌、紫花地丁加90%-95%的乙醇进行回流提取,提取液回收乙醇,在45℃-50℃下干燥,得干浸膏2;
e)合并干浸膏1和干浸膏2,将其粉碎成粉,再加入所述重量配比的竹沥干粉,混合均匀,再粉碎成细粉,喷入夏枯草、厚朴、石菖蒲、青皮、枳实挥发油,再次搅拌均匀,获得组方提取物约50克,50克组方提取物细粉过100目筛后,备用;
f) 取聚乙烯醇25克加入85%的乙醇100ml中浸泡过夜,滤过,沥干,重复处理一次,倾倒出乙醇将聚乙烯醇60℃烘干,备用;
g) 取步骤f)中醇提之后烘干的聚乙烯醇20克置于三角瓶中,加入蒸馏水200ml,在90℃的水浴上加热,使之溶化成胶液,滤过,备用;
h) 称取羧甲基纤维素钠和明胶各8克置于三角瓶中,加入蒸馏水160ml,在90℃水浴上加热并且不断搅拌,使其融化成胶液,滤过,备用;
i) 取步骤g)中获取的聚乙烯醇40ml置于蒸发皿中,加入h)步骤中获得的羧甲基纤维素钠和明胶的混合胶液40ml,加入甘油2ml,10滴聚山梨酯-80(10ml),混匀,静置脱气泡;
j) 取e)步骤中获取的中药组合物细粉加入步骤i)中获取的液体中,搅拌均匀,即得;用于涂膜使用。
【实施例5】本发明药物外贴剂制备
a)称取原料药物备用,药物配比如下:
仙人掌 32克 | 川芎 28克 | 紫花地丁 28克 | 夏枯草 24克 |
漏芦 24克 | 青皮 24克 | 枳实 24克 | 水仙根 20克 |
玉柏石松 20克 | 龙葵 20克 | 木槿花 20克 | 厚朴 20克 |
石菖蒲 20克 | 火焰草 14克 | 水栀 14克 | 皂角刺 14克 |
天花粉 14克 | 泽泻 14克 | 重楼 12克 | 四叶草 10克 |
竹沥 10克 | 生甘草 5克 |
b)将所述重量配比的川芎、漏芦、水仙根、玉柏石松、龙葵、木槿花、火焰草、水栀、皂角刺、天花粉、泽泻、重楼、四叶草、生甘草14味中药加水煎煮2次;第一次加水量以没过药面2cm为宜,沸腾之后文火煎煮50分钟;第二次加水量以没过药面1cm为宜,沸腾之后文火煎煮30分钟;合并两次煎液,过滤获得滤液1;
c)将所述重量配比的夏枯草、厚朴、石菖蒲、青皮、枳实用水蒸气提取方法收集挥发油备用。夏枯草、厚朴、石菖蒲、青皮、枳实的水煎液(水煎液获取方法同步骤b)与滤液1合并,浓缩成比重为1.35的浸膏,加90%-95%的乙醇进行醇沉,过滤沉淀后回收乙醇并浓缩,在45℃-50℃下干燥,制得干浸膏1;
d)将所述重量配比的仙人掌、紫花地丁加90%-95%的乙醇进行回流提取,提取液回收乙醇,在45℃-50℃下干燥,得干浸膏2;
e)合并干浸膏1和干浸膏2,将其粉碎成粉,再加入所述重量配比的竹沥干粉,混合均匀,再粉碎成细粉,喷入夏枯草、厚朴、石菖蒲、青皮、枳实挥发油,再次搅拌均匀,获得组方提取物约40克,40克组方提取物细粉过100目筛后,备用;
f)取聚乙烯醇25克加入85%的乙醇100ml中浸泡过夜,滤过,沥干,重复处理一次,倾倒出乙醇将聚乙烯醇60℃烘干,备用;
g)取f)步骤中醇提之后烘干的聚乙烯醇20克置于三角瓶中,加入蒸馏水200ml,在90℃的水浴上加热,使之溶化成胶液,滤过,备用;
h)称取羧甲基纤维素钠和明胶各8克置于三角瓶中,加入蒸馏水160ml,在90℃水浴上加热并且不断搅拌,使其融化成胶液,滤过,备用;
i)取步骤g)中获得的聚乙烯醇胶液40ml置于蒸发皿中,加入h)步骤中获得的羧甲基纤维素钠和明胶的混合胶液40ml,加入甘油2ml,10滴聚山梨酯-80(10ml),混匀,静置脱气泡;
取e)步骤中获取的中药组合物细粉加入上述溶液中,搅拌均匀;取用玻璃板(5cm*5cm)1块,洗净,干燥,用75%的乙醇擦拭消毒,再涂擦少许石蜡,用吸管配合洗耳球吸取上述药液10ml,滴注于玻璃板上,摊匀,水平面放置于半干,再置于60℃烘干,小心取下干药膜,用紫外线灭菌20分钟,装于无菌塑料袋中,即得。
效果例
1 临床资料
选取河北中医学院门诊2014年1月至2017年12月收治的哺乳期热邪壅盛型乳腺炎的患者86人,全部为女性患者。纳入病例中,平均年龄( 29.8±2.6)岁,平均产后时间( 65.2 ±3.15) 天,平均分娩孕周( 32.5±2.6) ,平均产次( 1.3±0.3) 次; 分娩方式为剖宫产者52例、顺产34例,全母乳喂养者56例、非全母乳喂养30例。以PEMS3.2 软件产生随机数表将患者随机分为两组(治疗组与对照组),治疗组平均年龄(30 .00 ±2 .70)岁, 平均产后时间(64 .47 ±5 .85)d ;对照组平均年龄(28 .93 ±2 .05)岁, 平均产后时间(66 .97 ±3 .90)d 。两组患者的基本临床资料差异无统计学意义(P >0 .05),具有可比性。
诊断标准
2.1 西医诊断标准:
以“WHO 乳腺炎指南( 2000 WHO/FCH/CAH/00.13) ”、《实用妇产科学》等参考资料中界定的急性乳腺炎诊断标准: ①产后或哺乳期女性出现单侧或双侧乳房疼痛性肿块,乳腺内肿块呈球形或橄榄形, 光滑, 肿块界限不清,稍有活动、弹性感,伴有明显的触痛,乳房局部皮肤红肿,同侧腋窝多无淋巴结肿大;彩超检查显示乳腺囊性、实性或混合性肿块。②可有畏寒、发热、乏力等全身症状。③查血常规示白细胞及中性粒细胞增多。有以上①项和②、③中的1-2项,即可诊断为急性乳腺炎。
中医诊断标准:
参照《现代中医乳房病学》、《中医病证诊断疗效标准》、《中药新药临床研究指导原则》中急性乳腺炎的诊断标准:①乳房内有疼痛性肿块,皮肤不红或微红,排乳不畅,可有乳头皲裂糜烂;②多有恶寒发热,头痛,周身不适等症;③患侧腋下可有核状肿大疼痛;④患者为哺乳妇女,以未满月的初产妇为多见;⑤血白细胞总数及中性粒细胞增高。结合中医望闻问切,确认为热邪壅盛证。
纳入标准:
①符合西医诊断标准和中医诊断标准;②无乳腺手术史;③年龄18~50周岁,患者处于哺乳期;④受试者知情同意,自愿受试并签署知情同意书。
排除标准
①合并脓毒血症或其他感染性疾病;②合并有心脑血管、肝肾和造血系统等原发性疾病或严重器质性病变;③精神疾病患者、不同意参加本研究者;④肾功能异常,或肝功能ALT、AST>1.5倍正常参考值上限者;⑤合并乳腺雷诺症或其他乳腺病理学疾病者;⑥不符合纳入标准、未按规定用药、年龄在18岁以下、过敏体质或对本药过敏者;⑦中途主动退出或失访者。
疗效评价标准
疗效标准参照《中医病证诊断疗效标准》。
治愈: 全身症状消失,乳房肿块完全消失,乳汁排泄通畅,血常规正常,体温正常;结合乳房彩超检查证实。
好转: 全身症状消失,肿块缩小50 %以上,乳汁排泄情况改善,血常规正常或明显改善,体温正常或明显降低,彩超检查证实相比缩小, 并与临床相符。
有效:全身症状明显减退,肿块缩小,乳汁排泄情况改善,血常规有所改善,体温降低,彩超检查证实肿块缩小, 并与临床相符。
未愈:肿块未见缩小,血常规及体温均未见改善,治疗前后相同或病情进展至成脓期。
观察指标
主要观察指标为治愈率、有效率。
治愈率(%)=治愈例数/总例数;
有效率(%)=(治愈+好转+有效)例数/总例数;
次要观察指标为乳房肿块积分、乳房肿块长径变化等。
治疗方法:
对照组给予硫酸镁溶液湿热敷治疗。方法: 以3~4层纱布浸湿50~ 60℃的50%硫酸镁溶液,拧至不滴水后对病侧乳房进行湿热敷,露出乳头,以利于乳汁排出。热敷期间根据温度酌情更换纱布。每次湿热敷30分钟,每日3次。
治疗组使用实施例1的中药组合物软膏剂外敷治疗,每次取适量均匀涂敷于纱布上,外敷于患处,外敷范围超出肿块边缘约2cm,露出乳头,以利于乳汁排出。每日3次,每次外敷约30分钟。
观察方法
观察时间为3个月,分别于初诊、30天、60天、90天进行相关指标测定。用乳腺彩色B超检查测量肿块长径。肿块积分方法参照2002年《中药新药临床研究指导原则》拟定。肿块大小以肿块长径算,分4级计分。0分:无肿块;2分:肿块≤2㎝;4分:2cm﹤肿块≤4㎝;6分:肿块>4㎝。
统计学方法
采用SPSS18 .0软件包进行统计。疗效分析采用Wilcoxon秩和检验;重复测量数据采用重复测量方差分析。
治疗结果:
临床疗效比较:治疗组总有效率达到97.67%,对照组的总有效率72.09%,两组疗效差异有统计学意义(P<0.05)。(见表1 )
表1 治疗组与对照组疗效比较
组别 | 患者数量 | 痊愈数量 | 好转数量 | 有效数量 | 无效数量 | 总有效率% |
治疗组 | 43 | 10 | 20 | 12 | 1 | 97.67%<sup>*</sup> |
对照组 | 43 | 3 | 17 | 11 | 12 | 72.09% |
注:与对照组比较,*P<0.05
乳房肿块积分变化情况组内比较, 两组30d 、60d 、90d 肿块积分差异均有统计学意义(P <0 .05);组间比较,两组30d 、60d 、90d 积分差异亦均有统计学意义(P <0 .05)(见表2)。
表2 两组乳房肿块积分比较
组别 | 患者数量 | 治疗前 | 30天 | 60天 | 90天 |
治疗组 | 43 | 4.96±1,32 | 3.14±0.98<sup>*#</sup> | 2.16±0.34<sup>*#Δ</sup> | 0.95±0.35<sup>*#ΔΦ</sup> |
对照组 | 43 | 4.85±1.19 | 3.57±0.65<sup>*</sup> | 2.58±0.56<sup>*Δ</sup> | 1,25±0.26<sup>*ΔΦ</sup> |
注:与本组治疗前比较, *P <0 .05;与本组30 天比较,ΔP<0.05;与本组60天比较,Φ P<0.05;与对照组同期比较,#P<0.05。
肿块长径变化情况。两组组内比较,30天、60天、90天肿块直径差异均有统计学意义(P <0 .05);组间30天、60天、90天肿块直径差异亦均有统计学意义(P <0 .05)(详见表3)。
表3 肿块长径变化比较
组别 | 患者数量 | 治疗前 | 30天 | 60天 | 90天 |
治疗组 | 43 | 47.65±5.54 | 25.09±5.95<sup>*#</sup> | 13.58±4.16<sup>*#Δ</sup> | 6.27±3.65<sup>*#ΔΦ</sup> |
对照组 | 43 | 46.35±3.25 | 27.77±3.78<sup>*</sup> | 15.56±3.18<sup>*Δ</sup> | 8.52±2.67<sup>*ΔΦ</sup> |
注:与本组治疗前比较, *P<0.05;与本组30天比较, ΔP<0.05;与本组60天比较, ΦP<0.05;与对照组同期比较, #P<0.05。
需要说明的是,实施例2-5所得的药物制剂的用量依照实施例1中的中药组合物含量进行折算,所述实施例2-5的有效率不低于95%。
【典型病例】
申某,女,32 岁。患者3天前自我感觉左侧乳房上方乳晕部轻微压痛,一天前疼痛加重,出现局部红肿压痛,难以忍受,住院治疗。入院诊断为急性乳腺炎。血常规: WBC 18.01,NEUT% 82.98%; 快速-C 反应蛋白: 139.83,超敏C反应蛋白大于5.00。要求患者停止哺乳,提出局部脓肿切开引流手术方案。患者要求中医保守治疗而到我院就诊。就诊之时T38.6℃,左侧乳房上方乳晕部红肿,触诊局部皮温高,有肿块,长径约4cm,按压局部患者疼痛,且压之不褪色,舌红,苔黄腻,脉滑数。了解患者诉求,结合患侧乳房诊察结果,采用本实施例1的软膏剂外敷于患处,嘱患者8h后自行更换膏剂。因使用抗生素,故嘱患者停止哺乳2天,自行手法排乳(避开患处)。三日后复诊,患者精神状况好转,乳房局部状况如前。T 38℃;复查血常规: WBC 20.65,NEUT% 87.56%;快速-C反应蛋白: 200.00,超敏C反应蛋白大于5.00。继续使用本实施例1的膏剂外敷治疗,用法同前。又三日后三诊:患者精神状况可,乳房肿块较前稍软,维持上述治疗。又三日,四诊: 患者自我感觉局部疼痛可耐受,局部红肿减轻,肿块变软,局部皮温下降,继续维持上述治疗。又三日,五诊: 患者精神状况好,乳房局部红肿压痛减轻,肿块减小变软。舌质偏红,苔黄,脉弦数。T 37.5℃,复查血常规:WBC11.06,NEUT% 43.50%。快速-C反应蛋白: 51.00,超敏C反应蛋白小于5.00,嘱患者健侧乳房恢复哺乳,患侧乳房自行手法排乳(避开患处)。又三日,六诊: 患者精神状况良好,患侧乳房轻微发红,按压有轻微疼痛,肿块消失,继续采用实施例1的膏剂外敷,巩固治疗3天。又3日,七诊: 患者全身症状消失,乳房肿块消散,乳房哺乳功能恢复,双乳形态正常。随访3个月未见复发。
柯某,女,42岁。产后3个月余,4天前出现左侧乳房红肿热痛,并且逐渐加重,无发热恶寒,于外院诊断为急性乳腺炎,就诊之时纳差,口渴,舌红,苔黄,脉滑数。体温36.9℃,专科查体见左侧乳房内上象限皮肤潮红,局部皮肤透亮,可触及最大约4cm×6cm质硬肿块,触痛明显,穿刺口未见脓性分泌物溢出。查血常规示:白细胞计数7.53×99 /L,中性粒细胞0.856。考虑急性乳腺炎脓肿尚未形成。西医诊断: 急性乳腺炎(初期) 。中医诊断: 乳痈(初期),辨证属热邪壅盛型。治宜清热解毒,散瘀止痛。治以本实施例4的膜剂外敷,8小时之后换药一次。五天之后二诊: 患者症状明显缓解,舌略红,舌苔黄渐退,脉弦细。查体见左侧乳房红肿消减,未触及明显硬结。复查血常规正常。继续维持上述外敷治法。又五天之后,三诊: 患者无明显不适,舌淡红,苔白,脉滑数。乳房未见变形,仍然维持上述治疗方法。又五天后,四诊: 患者左侧乳房红肿消退,乳房松软,急性乳腺炎痊愈。3个月后门诊随访,患者乳房松软,外形良好。
袁某,女,26岁,产后2个月。5年前因左乳房红肿疼痛而在当地医院治疗,经打针、服药、外敷药后痊愈。5天前双侧乳房肿痛又发,乳房肿痛伴有身热不适而来就诊。检查:患者体胖,舌红苔黄,脉弦滑数。两侧乳头扁平,乳晕及其两侧和下部肿胀,触痛,皮色鲜红,尚无溃口。诊断:哺乳期乳腺炎(哺乳期乳痈,气滞热盛证)。方选本实施例3的酊剂外涂,每日早上8:00至晚10:00每隔2个小时涂抹一次,睡眠停止涂抹,连用15日,乳晕及其两侧和下部肿胀、触痛减轻,皮色淡红;继续维持以上治疗方法,巩固15日,乳晕及其两侧和下部肿胀、触痛症状消失,乳房皮色、形态正常,随访6个月未见复发。
朱某,女,31岁,剖宫产后3月余,4天前因左侧乳房胀痛,伴有发热前来就诊,伴头晕、神疲、纳差,体温38.5℃。舌红,苔黄,脉数。诊断:急性乳腺炎(乳痈,热毒壅盛证)。治以本实施例2的中药组合物乳剂,早上8:00至晚上10:00,每隔2小时涂抹一次。治疗15天之后二诊:患者头晕、神疲、乏力减轻,纳食正常,继续使用上述方法巩固治疗15天后头晕、神疲、乏力症状消失,纳食正常,随访3个月未见复发。
Claims (9)
1.一种防治哺乳期妇女热邪壅盛型乳腺炎的中药组合物,其特征在于,其包括如下重量份的原料:
。
2.根据权利要求1所述的一种防治哺乳期妇女热邪壅盛型乳腺炎的中药组合物,其特征在于,其包括如下重量份的原料:
。
3.一种如权利要求1或2所述的防治哺乳期妇女热邪壅盛型乳腺炎的中药组合物的制备方法,其特征在于,其包括以下步骤:
(1)按照重量份秤取原料药物仙人掌、川芎、紫花地丁、夏枯草、漏芦、青皮、枳实、水仙根、玉柏石松、龙葵、木槿花、厚朴、石菖蒲、火焰草、水栀、皂角刺、天花粉、泽泻、重楼、四叶草、竹沥、生甘草备用;
(2)将所述重量配比的川芎、漏芦、水仙根、玉柏石松、龙葵、木槿花、火焰草、水栀、皂角刺、天花粉、泽泻、重楼、四叶草、生甘草加水煎煮2次;第一次加水量为没过药面2cm,沸腾之后文火煎煮50分钟;第二次加水量为没过药面1cm,沸腾之后文火煎煮30分钟;合并两次煎液,过滤获得滤液A;
(3)将所述重量配比的夏枯草、厚朴、石菖蒲、青皮、枳实用水蒸气提取方法收集挥发油备用;
(4)步骤(3)中收集了挥发油之后的夏枯草、厚朴、石菖蒲、青皮、枳实,继续利用步骤(2)得到水煎液A,所述水煎液A与滤液A合并,浓缩成比重为1.35的浸膏,再加90%-95%的乙醇进行醇沉,过滤沉淀后回收乙醇并浓缩,在45℃-50℃下干燥,制得干浸膏A;
(5)将所述重量配比的仙人掌、紫花地丁加90%-95%的乙醇进行回流提取,提取液回收乙醇,在45℃-50℃下干燥,得干浸膏B;
(6)合并干浸膏A和干浸膏B,将其粉碎成粉,再加入所述重量配比的竹沥干粉,混合均匀后再粉碎成细粉,喷入步骤(3)制得的夏枯草、厚朴、石菖蒲、青皮、枳实挥发油,再次搅拌均匀,即得。
4.一种包含权利要求1-3任一项所述的防治哺乳期妇女热邪壅盛型乳腺炎的中药组合物的中药制剂,其特征在于,其包括软膏剂、乳剂、酊剂、膜剂或外贴剂。
5.根据权利要求4所述的中药制剂,其特征在于,所述软膏剂的制备方法为,将所述中药组合物细粉过100目筛之后,加入液体石蜡(1克药粉配比液体石蜡4ml)研磨至均匀细腻的糊状,进而采用等量递增法分次递加凡士林至全量即得。
6.根据权利要求4所述的中药制剂,其特征在于,所述W/O型乳剂的制备方法为,取白蜂蜡、石蜡、液体石蜡,置于容器中,在水浴上加热熔化(1克中药组合物细粉配比白蜂蜡0.4克、石蜡0.4克、液体石蜡0.4ml),将中药组合物细粉溶解于70℃的水中,并且保持温度在70℃左右,充分溶解之后滤过不溶物,并且保持水相温度在70℃左右,将水相缓慢加入油相中,并且不断地向同一方向搅拌直至冷凝,即得。
7.根据权利要求4所述的中药制剂,其特征在于,所述酊剂的制备方法为,取中药组合物细粉,置于广口瓶中,加入80%的乙醇(1克中药组合物细粉配比5ml乙醇),密闭浸渍3-5天,密闭的过程中时时加以振摇,3-5天之后滤过,残渣压榨,合并滤液与压榨液,静置24小时,滤过,即得。
8.根据权利要求4所述的中药制剂,其特征在于,所述膜剂的制备方法为,取聚乙烯醇加入85%的乙醇(1克聚乙烯醇配比4ml乙醇)中浸泡过夜,滤过,沥干,重复处理一次,倾倒出乙醇,将聚乙烯醇60℃烘干,备用;取乙醇浸泡、烘干之后的聚乙烯醇置于三角瓶中,加入蒸馏水(1克乙醇浸泡之后烘干的聚乙烯醇配比10ml蒸馏水),在90℃的水浴上加热,使之溶化成胶液,滤过,备用;称取羧甲基纤维素钠和明胶置于三角瓶中(乙醇浸泡之后烘干的聚乙烯醇、羧甲基纤维素钠、明胶的质量比为5:2:2),加入蒸馏水(1克羧甲基纤维素钠配比20ml蒸馏水),在90℃水浴上加热并且不断搅拌,使其融化成胶液,滤过,备用;取上述制备成的聚乙烯醇胶液置于蒸发皿中,加入羧甲基纤维素钠和明胶的混合胶液(聚乙烯醇与羧甲基纤维素钠和明胶的混合胶液体积比为1:1),加入甘油(甘油与聚乙烯醇胶液的体积比为1:20)、聚山梨酯-80(聚山梨酯-80与聚乙烯醇胶液的体积比为1:4),混匀,静置脱气泡;取中药组合物细粉过100目筛之后加入上述液体中(过筛之后的中药组合物细粉与乙醇浸泡之后烘干的固体聚乙烯醇的重量比为2:1),搅拌均匀,即得。
9.根据权利要求4所述的中药制剂,其特征在于,所述外贴剂的制备方法为,取聚乙烯醇加入85%的乙醇中浸泡过夜(1克聚乙烯醇配比4ml乙醇),滤过,沥干,重复处理一次,倾倒出乙醇,将聚乙烯醇60℃烘干;
取乙醇浸泡之后烘干的聚乙烯醇置于三角瓶中,加入蒸馏水(1克乙醇浸泡之后烘干的聚乙烯醇配比10ml蒸馏水),在90℃的水浴上加热,使之溶化成胶液,滤过,备用;称取羧甲基纤维素钠和明胶置于三角瓶中(乙醇浸泡之后烘干的聚乙烯醇、羧甲基纤维素钠、明胶的质量比为5:2:2),加入蒸馏水(1克羧甲基纤维素钠配比20ml蒸馏水),在90℃水浴上加热并且不断搅拌,使其融化成胶液,滤过,备用;取上述制备获得的聚乙烯醇胶液置于蒸发皿中,加入羧甲基纤维素钠和明胶的混合胶液(聚乙烯醇胶液:羧甲基纤维素钠和明胶的混合胶液=1:1,体积比),加入甘油(甘油:聚乙烯醇胶液=1:20,体积比),加入聚山梨酯-80(聚山梨酯-80与聚乙烯醇胶液的体积比为1:4),混匀,静置脱气泡;取中药组合物细粉过100目筛之后加入上述液体中(过筛之后的中药组合物细粉与乙醇浸泡之后烘干的的聚乙烯醇固体的质量比为2:1),搅拌均匀; 取用玻璃板(玻璃板的尺寸依照实际需求确定),洗净,干燥,用75%的乙醇擦拭消毒,再涂擦少许石蜡,用吸管配合洗耳球吸取上述药液适量,滴注于玻璃板上,摊匀,水平面放置于半干,再置于60℃烘干,小心取下干药膜,用紫外线灭菌20分钟,装于无菌塑料袋中,即得。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811282197.7A CN109106877B (zh) | 2018-10-31 | 2018-10-31 | 一种防治哺乳期妇女热邪壅盛型乳腺炎的中药组合物、其制备方法及药物制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811282197.7A CN109106877B (zh) | 2018-10-31 | 2018-10-31 | 一种防治哺乳期妇女热邪壅盛型乳腺炎的中药组合物、其制备方法及药物制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109106877A true CN109106877A (zh) | 2019-01-01 |
CN109106877B CN109106877B (zh) | 2022-02-01 |
Family
ID=64855813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811282197.7A Active CN109106877B (zh) | 2018-10-31 | 2018-10-31 | 一种防治哺乳期妇女热邪壅盛型乳腺炎的中药组合物、其制备方法及药物制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109106877B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101843847A (zh) * | 2009-03-27 | 2010-09-29 | 潘治宇 | 治疗痄腮淋巴结肿大的中药组合物其制剂及其制备方法 |
CN105596461A (zh) * | 2015-11-13 | 2016-05-25 | 黄武 | 一种治疗乳腺炎的中药及其制备方法 |
CN108686157A (zh) * | 2018-08-16 | 2018-10-23 | 河北中医学院 | 一种防治瘀血阻滞型乳癖的中药组合物、其制备方法及药物制剂 |
-
2018
- 2018-10-31 CN CN201811282197.7A patent/CN109106877B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101843847A (zh) * | 2009-03-27 | 2010-09-29 | 潘治宇 | 治疗痄腮淋巴结肿大的中药组合物其制剂及其制备方法 |
CN105596461A (zh) * | 2015-11-13 | 2016-05-25 | 黄武 | 一种治疗乳腺炎的中药及其制备方法 |
CN108686157A (zh) * | 2018-08-16 | 2018-10-23 | 河北中医学院 | 一种防治瘀血阻滞型乳癖的中药组合物、其制备方法及药物制剂 |
Non-Patent Citations (1)
Title |
---|
赵筱丽: "蒲公英地丁汤治疗哺乳期急性乳腺炎96例", 《浙江中医杂志》 * |
Also Published As
Publication number | Publication date |
---|---|
CN109106877B (zh) | 2022-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105343625A (zh) | 一种排毒除湿利胆的蒲公英口服液及其制备方法 | |
CN102755596B (zh) | 一种治疗痰湿型乳腺增生的中药及制备方法 | |
CN104013868B (zh) | 一种治疗慢性阻塞性肺疾病的中药组合物及其制备方法 | |
CN102886014A (zh) | 一种清血消炎的抗肿瘤药物 | |
TW201221136A (en) | Treatment of varicose veins, hemorrhoids, hemorrhoids varicose veins organization, slow down the aging, skin whitening herbal extract concentrated composition | |
CN104338031A (zh) | 生白方中药饮片组合制剂、制备方法及组合包装 | |
CN104857271B (zh) | 增强机体免疫力中药饮片组合制剂、制备方法及组合包装 | |
CN105435197A (zh) | 一种治疗桥本氏病的药物组合物及其制备方法 | |
CN104998197A (zh) | 一种用于治疗肝癌的中药组合物 | |
CN104873805A (zh) | 一种治疗感冒的中药制剂、制备方法及应用 | |
CN103099885A (zh) | 具有祛痤疮功能软胶囊及其制备方法 | |
CN105709101A (zh) | 一种治疗睑缘炎的中药制剂及其制备方法 | |
CN109106877A (zh) | 一种防治哺乳期妇女热邪壅盛型乳腺炎的中药组合物、其制备方法及药物制剂 | |
CN105435190A (zh) | 用于治疗寒热错杂型哮病的中药组合物及其制备方法 | |
CN105106591A (zh) | 用于治疗牛肺水肿的药物及其制备方法 | |
CN104258224A (zh) | 一种治疗肺肾阴虚型慢性支气管炎的五味子口服液及其制备方法 | |
CN107875356A (zh) | 一种治疗胆囊息肉的中药制剂及其制备方法 | |
CN106110204A (zh) | 一种提高免疫力的蒲公英口服液及其制备方法 | |
CN105288166A (zh) | 一种用于甲状腺肿大的中药组合物及其制备方法 | |
CN106039075A (zh) | 一种治疗肺胃蕴热型慢性咽炎的中药组合物及方法 | |
CN105998979A (zh) | 一种治疗肺肾阴虚型慢性咽炎的中药组合物及方法 | |
CN104800519A (zh) | 一种治疗冲任失调型乳腺增生的药物及其制备方法 | |
CN105362784A (zh) | 一种治疗子宫肌瘤的中药组合物及其制备方法 | |
CN105434922A (zh) | 治疗面瘫的制剂及制法 | |
CN105106469A (zh) | 主治卵巢癌的中药组合物及制法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |